0001493152-23-017120.txt : 20230515 0001493152-23-017120.hdr.sgml : 20230515 20230515131855 ACCESSION NUMBER: 0001493152-23-017120 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 33 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230515 DATE AS OF CHANGE: 20230515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IR-Med, Inc. CENTRAL INDEX KEY: 0001839133 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 844516398 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-56492 FILM NUMBER: 23920523 BUSINESS ADDRESS: STREET 1: C/O ABOUDI LEGAL GROUP PLLC, 745 5TH AVE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10151 BUSINESS PHONE: 6467684285 MAIL ADDRESS: STREET 1: C/O ABOUDI LEGAL GROUP PLLC, 745 5TH AVE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10151 FORMER COMPANY: FORMER CONFORMED NAME: International Display Advertising, Inc. DATE OF NAME CHANGE: 20210105 10-Q 1 form10-q.htm
0001839133 false Q1 --12-31 http://fasb.org/us-gaap/2023#RelatedPartyMember http://fasb.org/us-gaap/2023#RelatedPartyMember P1Y P3Y 0001839133 2023-01-01 2023-03-31 0001839133 2023-05-15 0001839133 2023-03-31 0001839133 2022-12-31 0001839133 2022-01-01 2022-03-31 0001839133 us-gaap:CommonStockMember 2022-12-31 0001839133 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001839133 us-gaap:RetainedEarningsMember 2022-12-31 0001839133 us-gaap:CommonStockMember 2021-12-31 0001839133 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001839133 us-gaap:RetainedEarningsMember 2021-12-31 0001839133 2021-12-31 0001839133 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001839133 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001839133 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001839133 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001839133 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001839133 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001839133 us-gaap:CommonStockMember 2023-03-31 0001839133 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001839133 us-gaap:RetainedEarningsMember 2023-03-31 0001839133 us-gaap:CommonStockMember 2022-03-31 0001839133 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001839133 us-gaap:RetainedEarningsMember 2022-03-31 0001839133 2022-03-31 0001839133 IRME:EmployeeStockOptionOneMember 2023-01-01 2023-03-31 0001839133 IRME:EmployeeStockOptionOneMember 2023-03-31 0001839133 IRME:EmployeeStockOptionTwoMember 2023-01-01 2023-03-31 0001839133 IRME:EmployeeStockOptionTwoMember 2023-03-31 0001839133 IRME:EmployeeStockOptionThreeMember 2023-01-01 2023-03-31 0001839133 IRME:EmployeeStockOptionThreeMember 2023-03-31 0001839133 IRME:EmployeeStockOptionFourMember 2023-01-01 2023-03-31 0001839133 IRME:EmployeeStockOptionFourMember 2023-03-31 0001839133 us-gaap:CommonStockMember srt:MinimumMember 2023-03-31 0001839133 us-gaap:CommonStockMember srt:MaximumMember 2023-03-31 0001839133 srt:MinimumMember 2023-03-31 0001839133 srt:MaximumMember 2023-03-31 0001839133 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001839133 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001839133 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-03-31 0001839133 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-03-31 0001839133 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-03-31 0001839133 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-03-31 0001839133 srt:MinimumMember 2023-01-01 2023-03-31 0001839133 srt:MaximumMember 2023-01-01 2023-03-31 0001839133 srt:MinimumMember 2022-01-01 2022-03-31 0001839133 srt:MaximumMember 2022-01-01 2022-03-31 0001839133 us-gaap:PrivatePlacementMember us-gaap:WarrantMember 2021-04-30 0001839133 us-gaap:PrivatePlacementMember us-gaap:WarrantMember 2022-07-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:ILS utr:D

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

MARK ONE

☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

for the Quarterly Period ended March 31, 2023; or

 

☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

for the transition period from ________ to ________

 

Commission File Number: 000-56492

 

IR-Med, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada   84-4516398
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification No.)

 

ZHR Industrial Zone

Rosh Pina Israel

    
(Address of principal executive offices)   Zip Code

 

+ 972-4-655-5054

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
    Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

As of May 15, 2023, there were outstanding 68,829,424 shares of the registrant’s common stock, par value $0.001 per share.

 

 

 

 

 

 

IR-MED, INC.

Form 10-Q

March 31, 2023

 

  Page
   
PART I — FINANCIAL INFORMATION  
   
Item 1 – Unaudited Condensed Consolidated Financial Statements  
   
Condensed Consolidated Balance Sheets – March 31, 2023 and December 31, 2022(unaudited) 3
   
Condensed Consolidated Statements of Operations for the three months ended March 31, 2023 and 2022 (unaudited) 4
   
Condensed Consolidated Statement of Changes in Stockholders’ Equity for the three months ended March 31, 2023 and 2022 (unaudited) 5
   
Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2023 and 2022 (unaudited) 6
   
Notes to Unaudited Condensed Consolidated Financial Statements 7
   
Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations 11
   
Item 3 – Quantitative and Qualitative Disclosures About Market Risk 16
   
Item 4 – Controls and Procedures 17
   
PART II — OTHER INFORMATION 17
   
Item 1 – Legal Proceedings 17
   
Item 1A – Risk Factors 17
   
Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds 17
   
Item 3 – Defaults upon Senior Securities 18
   
Item 4 – Mine Safety Disclosures 18
   
Item 5 – Other Information 18
   
Item 6 – Exhibits 18
   
Exhibit Index 18
   
SIGNATURES 19

 

2

 

 

IR-Med ..Inc

 

Interim Unaudited Condensed Consolidated Balance Sheets

 

 

  

March 31

2023

  

December 31

2022

 
   U.S dollars (in thousands) 
Assets          
          
Current assets          
Cash and cash equivalents   2,103    3,002 
Accounts receivable   56    55 
Total current assets   2,159    3,057 
           
Non- current assets          
Long term restricted deposit   11    11 
Operating lease right of use assets   136    155 
Property and equipment, net   67    71 
Total non-current assets   214    237 
           
Total assets   2,373    3,294 
           
Liabilities and Stockholders’ equity          
           
Current liabilities          
Trade and other payables   468    500 
Stockholders’ loans   159    162 
Total current liabilities   627    662 
           
Non-current liabilities          
Long term lease liability   26    40 
Total liabilities   653    702 
           
Stockholders’ Equity          
Common Stock, par value $0.001 per share, 250,000,000, shares authorized. as of March 31, 2023 and December 31, 2022; 68,829,424 and 68,808,970 shares issued, respectively.   68    68 
Additional paid-in capital   12,932    12,454 
Accumulated deficit   (11,280)   (9,930)
Total Stockholders’ equity   1,720    2,592 
           
Total liabilities and stockholders’ equity   2,373    3,294 

 

The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements.

 

3

 

 

IR-Med ..Inc

 

Interim Unaudited Condensed Consolidated Statements of Operations

 

 

   2023   2022 
  

For the three-month

period ended March 31

 
   2023   2022 
   U.S dollars (in thousands) 
Research and development expenses
   605    477 
           
Marketing expenses   172    51 
           
General and administrative expenses   575    325 
           
Total operating loss   1,352    853 
           
Financial income, net   (2)   (4)
           
Loss for the period   1,350    849 
           
Basic and dilutive loss per common
stock (in dollars)		   (0.020)   (0.013)

 

The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements.

 

4

 

 

IR-Med ..Inc

 

Interim Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity

 

 

   Shares   Amount   Capital   deficit   equity 
   Common Stock   Additional       Total 
   Number of       paid-in   Accumulated   Stockholders’ 
   Shares   Amount   Capital   deficit   equity 
   U.S dollars (in thousands) 
For the three-month period ended March 31, 2023                    
                     
Balance as of January 1, 2023   68,808,970    68    12,454    (9,930)   2,592 
                          
Stock-based compensation   20,454    - *   478    -    478 
Loss for the period   -    -    -    (1,350)   (1,350)
                          
Balance as of March 31, 2023   68,829,424    68    12,932    (11,280)   1,720 

 

(*)Represents an amount less than US$ 1 thousand

 

   Common Stock   Additional       Total 
   Number of       paid-in   Accumulated   Stockholders’ 
   Shares   Amount   Capital   deficit   equity 
   U.S dollars (in thousands) 
For the three-month period ended March 31, 2022                    
                     
Balance as of January 1, 2022   64,601,649    64    7,503    (5,196)   2,371 
                          
Stock-based compensation   -    -    53         53 
Loss for the period   -    -    -    (849)   (849)
                          
Balance as of March 31, 2022   64,601,649    64    7,556    (6,045)   1,575 

 

The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements.

 

5

 

 

IR-Med ..Inc

 

Interim Unaudited Condensed Consolidated Statements of Cash Flows

 

 

   2023   2022 
   For the three-month period ended 
   March 31   March 31 
   2023   2022 
   U.S dollars (in thousands) 
         
Cash flows from operating activities          
Loss for the period   (1,350)   (849)
           
Adjustments to reconcile loss for the period to net cash          
used in operating activities:
          
Stock based compensation   478    53 
Depreciation   4    3 
Accrued financial income   (6)   (2)
Increase in accounts receivable   (1)   (80)
(Decrease) increase in trade and other payables   (25)   121 
           
Net cash used in operating activities   (900)   (754)
           
Cash flows from investing activities          
Purchase of property and equipment   -    (11)
increase in long term deposit   -    (9)
           
Net cash used in investing activities   -    (20)
           
Effect of exchange rate changes on cash and cash equivalents   1    (2)
           
Net Decrease in cash and cash equivalents   (899)   (776)
           
Cash and cash equivalents as at the beginning of the period   3,002    2,815 
           
Cash and cash equivalents as at the end of the period   2,103    2,039 
Supplemental disclosure of cash flow information:          
Non-cash transactions:          
(Decrease) increase in non-current assets from recording of rights of use assets   -    160 
Increase (decrease) in non-current liabilities from recording of liability of lease agreements   -    (160)

 

The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements.

 

6

 

 

IR-Med ..Inc

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

 

Note 1 - General

 

A.Description of Business

 

IR-Med, Inc. (OTC QB: IRME, hereinafter: the “Parent Company”) was incorporated in Nevada in 2007 and is a holding company.

 

The registered office of IR-Med, Inc. and the corporate headquarters and research facility of IR. Med Ltd. are located in Rosh Pina, Israel.

 

The Company is a development stage medical device company developing its technology through its Subsidiary and is utilizing Infra-Red light spectroscopy (IR) combined with Artificial Intelligence (AI) technology platform to develop non-invasive devices for various medical indications, by detecting and measuring various biomarkers and molecules in the blood and in human tissue in real-time. The initial product candidates which are currently in various stages of development are non-invasive, user friendly and designed to address the medical needs of large and growing target patient groups by offering earlier and more accurate information for detection, which is expected to reduce healthcare expenses and reducing the widespread reliance on antibiotics administration, and other interventional options optimizing the delivery of the targeted medical services and, as a result, improving the efficacy and safety of administered treatments.

 

  B. Going Concern

 

The Company is in its development stage and does not expect to generate significant revenue until such time as the Company shall have completed the design and development of its initial product candidate and obtained the requisite approvals to market the product. During the three months ended March 31, 2023, the Company has incurred losses of US$1,350 thousand and had a negative cash flow from operating activities of US$ 900 thousand. The accumulated deficit as of March 31, 2023 is US$ 11,280 thousand.

 

Management’s plans regarding these matters include continued development and marketing of its products, as well as seeking additional financing arrangements. Although management continues to pursue these plans, there is no assurance that the Company will be successful in raising the needed capital from revenues or financing on commercially acceptable terms. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Management’s plans regarding these matters include continued development and marketing of its products, as well as seeking additional financing arrangements. As a result of the Company’s financial condition, substantial doubt exists that the Company will be able to continue as a going concern for one year from the issuance date of this first quarter of 2023 Report.

 

7

 

 

IR-Med Inc.

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

 

Note 2 - Interim Unaudited Financial Information

 

The accompanying unaudited financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“U.S GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and therefore should be read in conjunction with the Company’s Annual Report on for the year ended December 31, 2022.

 

In the opinion of management, all adjustments considered necessary for a fair statement, consisting of normal recurring adjustments, have been included. Operating results for the three month period ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.

 

Use of Estimates:

 

The preparation of financial statements in conformity with U.S GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant items subject to such estimates and assumptions including fair value of warrants and the share-based compensation. Actual results could differ from those estimates.

 

Note 3 - Significant Accounting Policies

 

These interim unaudited condensed consolidated financial statements have been prepared according to the same accounting policies as those discussed in the Company’s Annual Report for the year ended December 31, 2022.

 

Note 4 - Stock options plan

 

On December 23, 2020 the Group’s board of directors approved and the shareholders adopted a share-based compensation plan (“2020 Incentive Stock Plan”) for future grants by the Parent Company.

 

As of March 31, 2023, the Parent Company awarded to its employees and service providers options to purchase up to 14,143,842 shares of Common Stock, of which options for 8,687,842 shares were at an exercise price of US$ 0.32 per share, options for 4,776,000 shares were at an exercise price of US$ 0.58 per share, options for 480,000 shares were at an exercise price of US$ 0.01 per share and options for 200,000 shares

 

8

 

 

IR-Med Inc.

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

 

Note 4 - Stock options plan (Cont’d)

 

were at an exercise price of $0.64 per share. As of March 31, 2023 options for 9,494,372 shares were vested and the remaining balance has a vesting period ranging between one to three years. The options are exercisable for periods ranging between three to ten years from the vesting date.

 

The grant was approved following the adoption of the 2020 incentive stock plan (hereinafter the “Plan”) by the Parent Company on December 23, 2020 and the adoption of the sub plan (the “Israeli appendix”) on April 29, 2021. The Group recorded in the statement of operations a non-cash expense of $478 thousands and $53 thousands during the three months ended March 31, 2023 and 2022 respectively.

 

The stock-based compensation expenses for the three months ended March 31, 2023 and 2022 were recognized in the statements of operations as follows;

   March 31, 2023   March 31, 2022 
   For the three-month period ended 
   March 31, 2023   March 31, 2022 
   US Dollars (In thousands) 
         
Research and development expenses   45    21 
Marketing expenses   159    - 
General and administrative expenses   274    32 
 Total stock based compensation   478    53 

 

The following table sets forth information about the weighted-average fair value of options granted to employees and service providers during the three month periods ended March 31, 2023 and 2022, using the Black- Scholes-Merton option-pricing model and the weighted-average assumptions used for such grants:

  

   For the three-month period ended 
   March 31, 2023   March 31, 2022 
         
Dividend yields (see (I) below)   0.0%   0.0%
Share price (in U.S. dollar) (see (II) below)   0.53    0.26 
Expected volatility (see (III) below)   114.29% - 95.37%   82.77% - 142.57%
Risk-free interest rates (see (IV) below)   3.61% - 4%   0.18% - 1.7%
Expected life (in years) (see (V) below)   5 - 14.79    1.5 - 14.79 

 

9

 

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

 

Note 4 - Stock options plan (Cont’d)

 

I.The Group used 0% as its expected dividend yield, based on historic policies and future plans.

 

II.The Parent-Company’s common stocks are quoted on the Over the Counter (“OTC”). However, the Group considers its share price as it is traded on OTC to not be an appropriate representation of fair value, since it is not traded on an active market. The Group determined that the market is inactive due to low level of activity of the Parent Company’s Common Stock, stale or non-current price quotes and price quotes that vary substantially either over time or among market makers. Consequently, the price of the Parent-Company’s Common Stock has been determined based on the April 2021 and July 2022 Private placement units of Common Stock and Warrants at a per unit purchase price of $0.64 and $0.88 respectively. In order to evaluate the price per share, the Warrant value has been deducted from the total unit price.

 

III.As the Company is at its early stage of operation, there is not sufficient historical volatility for the expected term of the stock options. Therefore, the Group uses an average historical share price volatility based on an analysis of reported data for a peer group of comparable publicly traded companies which were selected based upon industry similarities.

 

IV.The Group determined the risk-free interest rate by using a weighted-average equivalent to the expected term based on the U.S. Treasury yield curve in effect as of the date of grant.

 

V.The expected life of the granted options was determined based on the estimated behavior of the grantees; since most of the grantees are executives, the Company assumed that the large majority of the options will be exercised prior to their expiration.

 
10

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Forward-looking Statements

 

This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws, and is subject to the safe-harbor created by such Act and laws. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” the negative of such terms, or other variations thereon or comparable terminology. The statements herein and their implications are merely predictions and therefore inherently subject to known and unknown risks, uncertainties, assumptions and other factors that may cause actual results, performance levels of activity, or our achievements, or industry results to be materially different from those contemplated by the forward-looking statements. Except as required by law, we undertake no obligation to release publicly the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Further information on potential factors that could affect our business is described under the heading “Risk Factors” in in Part I, Item 1A, of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission, or the SEC, on March 29, 2023. As used in this quarterly report, the terms “we”, “us”, “our”, the “Company” and “IR-Med” mean IR-Med, Inc.. and our wholly-owned subsidiary IR. Med Ltd. unless otherwise indicated or as otherwise required by the context.

 

Overview

 

IR-Med is a development stage medical device company that is developing non-invasive devices for various medical indications, by detecting and measuring various biomarkers and molecules in the blood and in human tissue in real-time, allowing healthcare professionals to detect and measure different molecules in the blood and in human tissue in real-time without any invasive procedures. Our initial product candidates are currently in various stages of development.

 

Our initial product under development, which we call PressureSafe, is a handheld optical monitoring device that is being developed to support early detection of pressure injuries (PI) to the skin and underlying tissue, regardless of skin tone and which calibrated personally to each patient’s skin, primarily caused by prolonged pressure associated with bed confinement. Our skin-device-interphase development of personalized medical devices allows high accuracy readings from the human body in a non-invasive method, that may provide caregiver the optimal decision support-system in cases where uncertainties disturb physicians in their decision processes. We plan to launch as a decision support system (DSS) tool for care givers in Hospitals, Nursing homes and Home-Care companies,

 

We are also in the preliminary stage of research and development of an innovative otoscope, which we call Nobiotics, to support physicians with an immediate indication as to whether mid-ear infection (Otitis Media), a common malady in children, is of a bacterial origin and thus requiring antibiotic treatment, or of a viral origin and does not require antibiotic treatment.

 

Our technology platform utilizes Artificial Intelligence (AI). AI is a broad term generally used to describe conditions where a machine mimics “cognitive” functions associated with human intelligence, such as “learning” and “problem solving. Basic AI includes machine learning, where a machine uses algorithms to parse data, learn from it, and then make a determination or prediction about a given phenomenon. The machine is “trained” using large amounts of data and algorithms that provide it with the ability to learn how to perform the task.

 

The global diagnostics market is driven in large part by solutions that can be applied in healthcare settings, as these tools will drive decisions regarding specific treatments and the associated outlays. However, despite advances in medical imaging and other diagnostic tools, misdiagnosis remains a common occurrence. We believe that offering additional Decision Support Systems (DSS) tools may improve diagnoses and outcomes through the adoption of AI-based decision support tools.

 

11

 

 

Our initial focus is on the development of DSS solutions utilizing our proprietary platform for the pre-emptive diagnosis of pressure injuries (PI) and of mid-ear infections detection. Our current business plan focuses on two principal medical devices currently in development:

 

1. PressureSafe — a handheld optical monitoring device that is being developed to support early detection of pressure injuries (PI) to the skin and underlying tissue, primarily caused by prolonged pressure associated with bed confinement; and

 

2. Nobiotics, an innovative otoscope, being designed to support physicians with an immediate indication as to whether mid-ear infection (Otitis Media), a common malady in children, is of a bacterial origin and thus requiring antibiotic treatment, or of a viral origin and does not require antibiotic treatment.

 

Our product candidates are in various stages of development. The PressureSafe device is in an advanced stage of development and is planned to be our first go-to-market product, and the NoBiotics is in initial stage of research and development.

 

We have completed the development of the first generation PressureSafe prototype in the second quarter of 2022. In June 2022, IR Med. Ltd., our wholly owned subsidiary, entered into a study agreement with Beit Rivka, a Large Geriatric Hospital in Israel associated with Clalit, the largest Health Maintenance Organization (HMO) in Israel, to conduct a usability study of Pressuresafe. In August 2022, IR Med. Ltd., entered into an agreement with an Israeli boutique industrial design company specializing in the design of medical devices and diagnostic products servicing a broad array of companies, including large multinational companies, for the design of the PressureSafe device in its advanced configuration, which incorporates preliminary results from a usability study currently being performed in Israel, including feedback from healthcare professionals. In February 2023, our subsidiary IR-Med Ltd. entered into an agreement with Rabin Medical Center (RMC) in Israel to perform a usability study, as an additional study center to the current study that we have been performing at Beit-Rivka, a large geriatrics hospital in Israel. The agreement is to conduct a usability study of our proprietary and patent protected “PressureSafe” device, which we plan to launch as a decision support system (DSS) tool for care givers in Hospitals, Nursing homes and Home-Care companies.

 

We are currently working on completing the development of the commercial version of the PressureSafe device, planned to be launched during 2023, pending FDA clearance.

 

Distribution Agreement

 

In the third quarter of 2022, we began preparations in anticipation of commercialization of PressureSafe in the United States pending regulatory approvals. On October 7, 2022, IR. Med, Ltd. and PI Prevention Care LLC, a Delaware limited liability company (the “Distributor”) entered into an exclusive Distribution and License Agreement (the “Distribution Agreement”) pursuant to which the Distributor received exclusive royalty bearing rights to promote, market and sell solely in the United States our PressureSafe monitoring device.

 

The Distributor is a recently formed Delaware entity comprised of persons and other entities including Company shareholders, who are active in the markets relating to senior care facilities, hospitals, home care centers, hospital equipment distributors, among others, throughout the United States and who are familiar with and have wide experience in addressing and responding to the needs of these medical care organizations.

 

Under the Distribution Agreement, the Distributor is solely responsible for the distribution, marketing and sales of the PressureSafe and its accompanying components and agreed undertake all commercially reasonable efforts to establish the necessary distribution and sales network for the Products by not later than the date on which the Company shall have received all regulatory and other clearance required to launch the commercialization of the PressureSafe Solution (such Date being the “Commercial Launch Date”). Prior to the Commercial Launch Date, the Distributor is to invest such resources as is reasonable such that upon the occurrence of the Commercial Launch Date there will be a commercially reasonable distribution network in place for the immediate marketing of the Product.

 

12

 

 

The Distribution Agreement provides for the payment of annual licensing fees. The Distribution Agreement also specifies the prices of each component of the Products payable to the Company and also provides for minimum annual purchase requirements of Product components in order to maintain exclusivity. If for whatever reason the Distributor does not comply with the minimum purchase requirements in any year, the Distributor can continue to have a non-exclusive license and distribution rights in the United States if the Distributor pays the annual license fee.

 

Subject to the compliance by the Distributor of its obligation under the Distribution Agreement, including the purchase by the Distributor of minimum annual purchase requirements of the components of the Products, the Distribution Agreement continues in effect for a term of thirteen years following the Commercial Launch Date. At the end of the initial three and eight year period, the parties are to enter into good faith negotiations as to the pricing of the Products and the minimum purchase quantities for the subsequent period. The Distributor also agreed to not distribute any products that compete with the Products.

 

Distribution and Revenue Generation

 

We intend to establish sales and marketing structures and strategic partnerships in the United States, UK and in Europe to support all of our product candidates.

 

The target markets for our PressureSafe device are relevant Health care setting (i.e., hospitals, senior care facilities, home care companies etc.), nursing homes and a growing segment of long terms home care givers. Towards that end, in third quarter of 2022, we began preparations in anticipation of commercialization of PressureSafe in the United States during 2023, pending regulatory approvals.

 

Once we receive the appropriate sales approvals, we expect the marketing will be done with local partners who have the relevant abilities and connections per each territory the company will ask to sell the products at. Since each country has its own specific healthcare system, a local partner (one or more) will be chosen to address the specific market needs- in terms of regulation, technical support and so on. Pricing will be determined by the local partner, taking in account all overhead expected costs, regulation requirements and reimbursement methods.

 

Nobiotics’ target users will be pediatricians, family doctors and Ear, Nose and Throat (ENT) doctors. The distribution of the Nobiotics is expected to be carried out by companies who are suppling devices and disposables to the target audience.

 

In both the PressureSafe and the Nobiotics devices, the revenue stream is expected to be generated mainly from the disposables and PSaaS (PressureSafe solution as a service) that are needed for the proper operation of the device, while the device itself likely be given under lease agreements. It is envisioned that the disposable component will be mass produced.

 

It is expected that market penetration for Nobiotics will be achieved through OEM agreements with one of several large medical device companies, already selling to the target market. At the current time, we have no commitments from any such distributors or OEM partners.

 

Key Financial Terms and Metrics

 

The following discussion summarizes the key factors our management believes are necessary for an understanding of our consolidated financial statements.

 

Revenues

 

We have not generated any revenues from product sales to date.

 

Research and Development Expenses

 

The process of researching and developing our product candidates is lengthy, unpredictable, and subject to many risks. We expect to continue incurring substantial expenses for the next several years as we continue to develop our product candidates. We are unable, with any certainty, to estimate either the costs or the timelines in which those expenses will be incurred. Our current development plans focus on the development of our PressureSafe and Nobiotics diagnostic devices. The design and development of these devices will consume a large proportion of our current, as well as projected, resources.

 

13

 

 

Our research and development costs include costs are comprised of:

 

● internal recurring costs, such as personnel-related costs (salaries, employee benefits, equity compensation and other costs), materials and supplies, facilities and maintenance costs attributable to research and development functions; and

 

● fees paid to external parties who provide us with contract services, such as preclinical testing, manufacturing and related testing and clinical trial activities.

 

Marketing

 

Marketing expenses consist primarily of salaries, employee benefits, equity compensation, and other personnel-related costs associated with executive and other support staff. Other significant marketing expenses include the costs associated with professional fees to develop our marketing strategy.

 

General and Administrative Expenses

 

General and administrative expenses consist primarily of salaries, employee benefits, equity compensation, and other personnel-related costs associated with executive, administrative and other support staff. Other significant general and administrative expenses include the costs associated with professional fees for accounting, auditing, insurance costs, consulting and legal services, along with facility and maintenance costs attributable to general and administrative functions.

 

Financial Expenses

 

Financial expenses consist primarily impact of exchange rate derived from re-measurement of monetary balance sheet items denominated in non-dollar currencies. Other financial expenses include bank’s fees and interest on long term loans.

 

Results of Operations

 

Comparison of the Three Months Ended March 31, 2023 to the Three Months Ended March 31, 2022

 

  

For the three months ended

March 31,

 
   2023   2022 
   U.S dollars (in thousands) 
     
Research and development expenses   605    477 
Marketing expenses   172    51 
General and administrative expenses   575    325 
Total operating expenses   1,352    853 
           
Financial income, net   (2)   (4)
           
Loss for the period   1,350    849 

 

Revenues. During the three-month period ended March 31, 2023 and 2022, we did not recorded any revenues from operation.

 

14

 

 

Research and Development Expenses- Research and development expenses consist of salaries and related expenses, consulting fees, service providers’, costs, and overhead expenses. Research and development expenses increased from $ 477,000 during the three months ended March 31, 2022 to $605,000 during the corresponding three month period in 2023. The increase in 2023 period resulted primarily from the recruitment of employees, increased use of third party contractors for further research and development activities, the performance of usability studies for our PressureSafe device and non-cash expenses recorded respecting stock based compensation to employees and service providers.

 

Marketing Expenses – Marketing expenses consist primarily of salaries and professional services. Marketing expenses increased from $51,000 during the three months ended March 31, 2022 to $172,000 during the corresponding three month period in 2023. The increase in marketing expenses resulted primarily from non-cash expenses attributable to stock-based compensation to service providers.

 

General and Administrative Expenses. General and administrative expenses consist primarily of salaries and related expenses and other non-personnel related expenses such as legal and accounting related expenses. General and Administrative expense increased from $325,000 during the three months ended March 31, 2022 to $575,000 in the corresponding three-months period in 2023. The increase in general and administrative expenses

resulted primarily from non-cash expenses attributable to stock-based compensation to our directors, officers and service providers.

 

Loss. Loss for the three months ended March 31, 2023 was $1,350,000 compared to $849,000 for the corresponding three month period in 2023. The increase in net loss is primarily attributable to non-cash expenses attributable to stock-based compensation to directors, officers and service providers, utilization of third party contractors for further research and development activities and the conduct of usability studies for our PressureSafe device.

 

Financial Condition, Liquidity and Capital Resources

 

We are subject to risks common to companies in the medical device industry, including but not limited to, the need for additional capital, the need to obtain marketing approval and reimbursement for any product candidate that we may identify and develop, the need to successfully commercialize and gain market acceptance of our product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development of technological innovations by competitors, reliance on third-party manufacturers and the ability to transition from pilot-scale production to large-scale manufacturing of products.

 

From inception, we have funded our operations from a combination of loans and sales of equity instruments. In 2021 and 2022, we raised aggregate gross proceeds of $5,830,000 and $3,625,000, respectively, from sales of our equity and equity linked securities.

 

As of March 31, 2023, we had $2,103,000 in cash resources and approximately $653,000 of liabilities, including of $627,000 of current liabilities from operations.

 

The following table provides a summary of operating, investing, and financing cash flows for the three months ended March 31, 2023 (in thousands):

 

   For the three months ended 
   March 31, 2023   March 31, 2022 
   US Dollars (In thousands) 
Net cash used in operating activities   (900)   (754)
Net cash used in investing activities   -    (20)

 

We have experienced operating losses since inception and had a total accumulated deficit of $11,280,000 as of March 31, 2023. We expect to incur additional costs and will require additional capital to realize our business plans. These losses have resulted in significant cash used in operations. During the three months ended March 31, 2023 and 2022, our cash used in operations was approximately $900,000 and $754,000, respectively. We need to continue and intensify our research and development efforts for our product candidates (which are in various stages of development), strengthen our patent portfolio, establish operations processes, and pursue FDA clearance and international regulatory approvals. As we continue to conduct these activities, we expect the cash needed to fund operations to increase significantly over the next several years.

 

15

 

 

We need to obtain additional funding in order to pursue our business plans. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.

 

We expect that our existing cash and cash equivalents will enable us to fund our operations and capital expenditure requirements through the fourth quarter of 2023. Our requirements for additional capital during this period will depend on many factors, including the following:

 

  ●

the scope, rate of progress, results and cost of our development and engineering efforts to develop the PressureSafe and Nobiotics devices, clinical studies (to the extent necessary), preliminary testing activities and other related activities;

  ● the cost, timing and outcomes of regulatory related efforts for commercial sales approvals;
  ● the cost and timing of establishing sales, marketing and distribution capabilities;
  ● the terms and timing of any collaborative, licensing and other arrangements that we may establish;
  ● the timing, receipt and amount of sales, profit sharing or royalties, if any, from our potential products;
  ●

the cost of preparing, filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and

  ●

the extent to which we acquire or invest in businesses, products or technologies, although we currently have no commitments or agreements relating to any of these types of transactions.

 

For the three months ended March 31, 2023 and as of the date of this report, we assessed our financial condition and concluded that based on our current and projected cash resources and commitments, as well as other factors mentioned above, there is a substantial doubt about our ability to continue as a going concern. We are planning to raise additional capital to continue our operations, as well as to explore additional avenues to increase revenues and reduce expenditures. We cannot be sure that future funding will be available to us on acceptable terms, or at all. Due to often volatile nature of the financial markets, equity and debt financing may be difficult to obtain.

 

We may seek to raise any necessary additional capital through a combination of private or public equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. To the extent that we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights, future revenue streams, or product candidates or to grant licenses on terms that may not be favorable to us. If we raise additional capital through private or public equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

A smaller reporting company, as defined by § 229.10(f)(1), is not required to provide the information required by this Item.

 

16

 

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

As of March 31, 2023, we conducted an evaluation under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, regarding the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (the “Exchange Act”). The term “disclosure controls and procedures” means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the requisite time periods and that such disclosure controls and procedures were effective to ensure that information required to be disclosed by the company in the reports that it files or submits under the Exchange Act is accumulated and communicated to its management, including its principal executive and principal accounting officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based on the evaluation of our disclosure controls and procedures as of March 31, 2023, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at reasonable assurance level, as further described below.

 

Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis.

 

Changes in Internal Control Over Financial Reporting

 

During the quarter ended March 31, 2023, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

PART II—OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

The Company is not currently involved in any legal proceedings. However, from time to time we may become involved in various legal proceedings that arise in the ordinary course of business, including actions related to our intellectual property. Although the outcomes of these legal proceedings cannot be predicted with certainty, we are currently not aware of any such legal proceedings that arise in the ordinary course of business, including actions related to our intellectual property. Although the outcomes of these legal proceedings cannot be predicted with certainty, we are currently not aware of any such legal proceedings or claims that we believe, either individually or in the aggregate, will have a material adverse effect on our business, financial condition, or results of operations.

 

ITEM 1A. RISK FACTORS

 

An investment in the Company’s Common Stock involves a number of very significant risks. You should carefully consider the risk factors included in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on March 29, 2023, in addition to other information contained in our reports and in this quarterly report in evaluating the Company and its business before purchasing shares of our Common Stock. There have been no material changes to our risk factors contained in our Annual Report on Form 10-K for the year ended December 31, 2022.

 

ITEM 2. UNREGISTERED SALES OF SECURITIES AND USE OF PROCEEDS

 

N/A

 

17

 

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

N/A

 

ITEM 5. OTHER INFORMATION:

 

None

 

ITEM 6. EXHIBITS

 

Exhibit Index:

 

31.1   Certification of Chief Executive Officer (Principal Executive Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934
     
31.2   Certification of Chief Financial Officer (Principal Financial and Accounting Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934
     
32.1   Certification of Chief Executive Officer (Principal Executive Officer), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
32.2   Certification of Chief Financial Officer (Principal Financial and Accounting Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934
     
101.INS   Inline XBRL Instance Document
     
101.SCH   Inline XBRL Taxonomy Extension Schema
     
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase
     
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase
     
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase
     
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

*** Portion of the Exhibit have been omitted.

 

18

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

IR-Med, Inc.

(Registrant)

 

By: /s/ Moshe Gerber   By: /s/ Sharon Levkoviz
  Moshe Gerber     Sharon Levkoviz
  Chief Executive Officer     Chief Financial Officer
  (Principal Executive Officer)     (Principal Financial and Accounting Officer)
         
Date: May 15, 2023   Date: May 15, 2023

 

19

 EX-31.1 2 ex31-1.htm

 

EXHIBIT 31.1

 

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Moshe Gerber, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of IR-Med, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

By: /s/ Moshe Gerber  
 

Moshe Gerber, Chief Executive Officer

(Principal Executive Officer)

  
     
Date: May 15, 2023  

 

 

 

 EX-31.2 3 ex31-2.htm

 

EXHIBIT 31.2

 

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Sharon Levkoviz, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of IR-Med, Inc..;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

By: /s/ Sharon Levkoviz  
 

Sharon Levkoviz, Chief Financial Officer

(Principal Financial and Accounting Officer)

  
     
Date: May 15, 2023  

 

 

 

 EX-32.1 4 ex32-1.htm

 

EXHIBIT 32.1

 

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

 

Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned Principal Executive Officer of IR-Med, Inc. (the “Company”) hereby certifies to such officer’s knowledge that:

 

(i) the accompanying Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

 

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ Moshe Gerber  

Moshe Gerber, Chief Executive Officer

(Principal Executive Officer)

  

 

Dated: May 15, 2023  

 

 

 

 

 EX-32.2 5 ex32-2.htm

 

EXHIBIT 32.2

 

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

 

Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned Principal Executive Officer of IR-Med, Inc.. (the “Company”) hereby certifies to such officer’s knowledge that:

 

(i) the accompanying Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

 

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ Sharon Levkoviz  

Sharon Levkoviz, Chief Financial Officer

(Principal Financial and Accounting Officer)

  

 

Dated: May 15, 2023  

 

 

 

 EX-101.SCH 6 irme-20230331.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - General link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Interim Unaudited Financial Information link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Stock options plan link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Stock options plan (Tables) link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - General (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Schedule of Stock-Based Compensation Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Schedule of Stock Options, Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Schedule of Stock Options, Valuation Assumptions (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Stock options plan (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 irme-20230331_cal.xml INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 irme-20230331_def.xml INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 irme-20230331_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Award Type [Axis] Employee Stock Option One [Member] Employee Stock Option Two [Member] Employee Stock Option Three [Member] Employee Stock Option Four [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Income Statement Location [Axis] Research and Development Expense [Member] Selling and Marketing Expense [Member] General and Administrative Expense [Member] Sale of Stock [Axis] Private Placement [Member] Warrant [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] Assets Current assets Cash and cash equivalents Accounts receivable Total current assets Non- current assets Long term restricted deposit Operating lease right of use assets Property and equipment, net Total non-current assets Total assets Liabilities and Stockholders’ equity Current liabilities Trade and other payables Stockholders’ loans Total current liabilities Non-current liabilities Long term lease liability Total liabilities Stockholders’ Equity Common Stock, par value $0.001 per share, 250,000,000, shares authorized. as of March 31, 2023 and December 31, 2022; 68,829,424 and 68,808,970 shares issued, respectively. Additional paid-in capital Accumulated deficit Total Stockholders’ equity Total liabilities and stockholders’ equity Other Liability, Current, Related and Nonrelated Party Status [Extensible Enumeration] Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Research and development expenses Marketing expenses General and administrative expenses Total operating loss Financial income, net Loss for the period Basic and dilutive loss per common stock (in dollars) Statement [Table] Statement [Line Items] Beginning balance, value Balance, shares Stock-based compensation Stock-based compensation, shares Loss for the period Stock-based compensation Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities Adjustments to reconcile loss for the period to net cash Stock based compensation Depreciation Accrued financial income Increase in accounts receivable (Decrease) increase in trade and other payables Net cash used in operating activities Cash flows from investing activities Purchase of property and equipment increase in long term deposit Net cash used in investing activities Effect of exchange rate changes on cash and cash equivalents Net Decrease in cash and cash equivalents Cash and cash equivalents as at the beginning of the period Cash and cash equivalents as at the end of the period Non-cash transactions: (Decrease) increase in non-current assets from recording of rights of use assets Increase (decrease) in non-current liabilities from recording of liability of lease agreements Organization, Consolidation and Presentation of Financial Statements [Abstract] General Quarterly Financial Information Disclosure [Abstract] Interim Unaudited Financial Information Accounting Policies [Abstract] Significant Accounting Policies Share-Based Payment Arrangement [Abstract] Stock options plan Schedule of Stock-Based Compensation Expenses Schedule of Stock Options, Valuation Assumptions Net losses Cash flow from operating activities net Accumulated deficit Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]  Total stock based compensation Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Dividend yields Share price Expected volatility minimum Expected volatility maximum Risk free interest rate minimum Risk free interest rate maximum Expected life (in years) Warrant exercise price per share Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary, Sale of Stock [Line Items] Dividend rate Purchase plans employees Stock issued during period shares issued for services Shares issued price per share Shares vested grant Warrants and rights outstanding term Share based compensation Net cash flows provided by used in operating activities. Assets, Current Assets, Noncurrent Assets [Default Label] Liabilities, Current Liabilities Equity, Attributable to Parent Liabilities and Equity Operating Income (Loss) Nonoperating Income (Expense) Shares, Outstanding APIC, Share-Based Payment Arrangement, Increase for Cost Recognition IncreaseDecreaseInAccruedFinancialExpenses Increase (Decrease) in Accounts Receivable Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment IncreaseInLongTermDeposit Net Cash Provided by (Used in) Investing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations NetCashFlowsProvidedByUsedInOperatingActivities EX-101.PRE 10 irme-20230331_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover - shares
 3 Months Ended
Mar. 31, 2023
May 15, 2023
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Mar. 31, 2023  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2023  
Current Fiscal Year End Date --12-31  
Entity File Number 000-56492  
Entity Registrant Name IR-Med, Inc.  
Entity Central Index Key 0001839133  
Entity Tax Identification Number 84-4516398  
Entity Incorporation, State or Country Code NV  
Entity Address, Address Line One ZHR Industrial Zone  
Entity Address, City or Town Rosh Pina  
Entity Address, Country IL  
City Area Code 972  
Local Phone Number 4-655-5054  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Elected Not To Use the Extended Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   68,829,424
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets    
Cash and cash equivalents $ 2,103 $ 3,002
Accounts receivable 56 55
Total current assets 2,159 3,057
Non- current assets    
Long term restricted deposit 11 11
Operating lease right of use assets 136 155
Property and equipment, net 67 71
Total non-current assets 214 237
Total assets 2,373 3,294
Current liabilities    
Trade and other payables 468 500
Stockholders’ loans 159 162
Total current liabilities 627 662
Non-current liabilities    
Long term lease liability 26 40
Total liabilities 653 702
Stockholders’ Equity    
Common Stock, par value $0.001 per share, 250,000,000, shares authorized. as of March 31, 2023 and December 31, 2022; 68,829,424 and 68,808,970 shares issued, respectively. 68 68
Additional paid-in capital 12,932 12,454
Accumulated deficit (11,280) (9,930)
Total Stockholders’ equity 1,720 2,592
Total liabilities and stockholders’ equity $ 2,373 $ 3,294
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Mar. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Other Liability, Current, Related and Nonrelated Party Status [Extensible Enumeration] us-gaap:RelatedPartyMember us-gaap:RelatedPartyMember
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 250,000,000 250,000,000
Common stock, shares issued 68,829,424 68,808,970
Common stock, shares outstanding 68,829,424 68,808,970
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]    
Research and development expenses $ 605 $ 477
Marketing expenses 172 51
General and administrative expenses 575 325
Total operating loss 1,352 853
Financial income, net (2) (4)
Loss for the period $ 1,350 $ 849
Basic and dilutive loss per common stock (in dollars) $ (0.020) $ (0.013)
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2021 $ 64 $ 7,503 $ (5,196) $ 2,371
Balance, shares at Dec. 31, 2021 64,601,649      
Loss for the period (849) (849)
Stock-based compensation 53   53
Balance at Mar. 31, 2022 $ 64 7,556 (6,045) 1,575
Balance, shares at Mar. 31, 2022 64,601,649      
Beginning balance, value at Dec. 31, 2022 $ 68 12,454 (9,930) 2,592
Balance, shares at Dec. 31, 2022 68,808,970      
Stock-based compensation [1] 478 478
Stock-based compensation, shares 20,454      
Loss for the period (1,350) (1,350)
Balance at Mar. 31, 2023 $ 68 $ 12,932 $ (11,280) $ 1,720
Balance, shares at Mar. 31, 2023 68,829,424      
[1] Represents an amount less than US$ 1 thousand
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Cash flows from operating activities    
Loss for the period $ (1,350) $ (849)
Adjustments to reconcile loss for the period to net cash    
Stock based compensation 478 53
Depreciation 4 3
Accrued financial income (6) (2)
Increase in accounts receivable (1) (80)
(Decrease) increase in trade and other payables (25) 121
Net cash used in operating activities (900) (754)
Cash flows from investing activities    
Purchase of property and equipment (11)
increase in long term deposit (9)
Net cash used in investing activities (20)
Effect of exchange rate changes on cash and cash equivalents 1 (2)
Net Decrease in cash and cash equivalents (899) (776)
Cash and cash equivalents as at the beginning of the period 3,002 2,815
Cash and cash equivalents as at the end of the period 2,103 2,039
Non-cash transactions:    
(Decrease) increase in non-current assets from recording of rights of use assets 160
Increase (decrease) in non-current liabilities from recording of liability of lease agreements $ (160)
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.1
General
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
General

Note 1 - General

 

A.Description of Business

 

IR-Med, Inc. (OTC QB: IRME, hereinafter: the “Parent Company”) was incorporated in Nevada in 2007 and is a holding company.

 

The registered office of IR-Med, Inc. and the corporate headquarters and research facility of IR. Med Ltd. are located in Rosh Pina, Israel.

 

The Company is a development stage medical device company developing its technology through its Subsidiary and is utilizing Infra-Red light spectroscopy (IR) combined with Artificial Intelligence (AI) technology platform to develop non-invasive devices for various medical indications, by detecting and measuring various biomarkers and molecules in the blood and in human tissue in real-time. The initial product candidates which are currently in various stages of development are non-invasive, user friendly and designed to address the medical needs of large and growing target patient groups by offering earlier and more accurate information for detection, which is expected to reduce healthcare expenses and reducing the widespread reliance on antibiotics administration, and other interventional options optimizing the delivery of the targeted medical services and, as a result, improving the efficacy and safety of administered treatments.

 

  B. Going Concern

 

The Company is in its development stage and does not expect to generate significant revenue until such time as the Company shall have completed the design and development of its initial product candidate and obtained the requisite approvals to market the product. During the three months ended March 31, 2023, the Company has incurred losses of US$1,350 thousand and had a negative cash flow from operating activities of US$ 900 thousand. The accumulated deficit as of March 31, 2023 is US$ 11,280 thousand.

 

Management’s plans regarding these matters include continued development and marketing of its products, as well as seeking additional financing arrangements. Although management continues to pursue these plans, there is no assurance that the Company will be successful in raising the needed capital from revenues or financing on commercially acceptable terms. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Management’s plans regarding these matters include continued development and marketing of its products, as well as seeking additional financing arrangements. As a result of the Company’s financial condition, substantial doubt exists that the Company will be able to continue as a going concern for one year from the issuance date of this first quarter of 2023 Report.

 

 

IR-Med Inc.

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

 
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Interim Unaudited Financial Information
 3 Months Ended
Mar. 31, 2023
Quarterly Financial Information Disclosure [Abstract]  
Interim Unaudited Financial Information

Note 2 - Interim Unaudited Financial Information

 

The accompanying unaudited financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“U.S GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and therefore should be read in conjunction with the Company’s Annual Report on for the year ended December 31, 2022.

 

In the opinion of management, all adjustments considered necessary for a fair statement, consisting of normal recurring adjustments, have been included. Operating results for the three month period ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.

 

Use of Estimates:

 

The preparation of financial statements in conformity with U.S GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant items subject to such estimates and assumptions including fair value of warrants and the share-based compensation. Actual results could differ from those estimates.

 
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Significant Accounting Policies
 3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Significant Accounting Policies

Note 3 - Significant Accounting Policies

 

These interim unaudited condensed consolidated financial statements have been prepared according to the same accounting policies as those discussed in the Company’s Annual Report for the year ended December 31, 2022.

 
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Stock options plan
 3 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Stock options plan

Note 4 - Stock options plan

 

On December 23, 2020 the Group’s board of directors approved and the shareholders adopted a share-based compensation plan (“2020 Incentive Stock Plan”) for future grants by the Parent Company.

 

As of March 31, 2023, the Parent Company awarded to its employees and service providers options to purchase up to 14,143,842 shares of Common Stock, of which options for 8,687,842 shares were at an exercise price of US$ 0.32 per share, options for 4,776,000 shares were at an exercise price of US$ 0.58 per share, options for 480,000 shares were at an exercise price of US$ 0.01 per share and options for 200,000 shares

 

 

IR-Med Inc.

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

 

Note 4 - Stock options plan (Cont’d)

 

were at an exercise price of $0.64 per share. As of March 31, 2023 options for 9,494,372 shares were vested and the remaining balance has a vesting period ranging between one to three years. The options are exercisable for periods ranging between three to ten years from the vesting date.

 

The grant was approved following the adoption of the 2020 incentive stock plan (hereinafter the “Plan”) by the Parent Company on December 23, 2020 and the adoption of the sub plan (the “Israeli appendix”) on April 29, 2021. The Group recorded in the statement of operations a non-cash expense of $478 thousands and $53 thousands during the three months ended March 31, 2023 and 2022 respectively.

 

The stock-based compensation expenses for the three months ended March 31, 2023 and 2022 were recognized in the statements of operations as follows;

   March 31, 2023   March 31, 2022 
   For the three-month period ended 
   March 31, 2023   March 31, 2022 
   US Dollars (In thousands) 
         
Research and development expenses   45    21 
Marketing expenses   159    - 
General and administrative expenses   274    32 
 Total stock based compensation   478    53 

 

The following table sets forth information about the weighted-average fair value of options granted to employees and service providers during the three month periods ended March 31, 2023 and 2022, using the Black- Scholes-Merton option-pricing model and the weighted-average assumptions used for such grants:

  

   For the three-month period ended 
   March 31, 2023   March 31, 2022 
         
Dividend yields (see (I) below)   0.0%   0.0%
Share price (in U.S. dollar) (see (II) below)   0.53    0.26 
Expected volatility (see (III) below)   114.29% - 95.37%   82.77% - 142.57%
Risk-free interest rates (see (IV) below)   3.61% - 4%   0.18% - 1.7%
Expected life (in years) (see (V) below)   5 - 14.79    1.5 - 14.79 

 

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

 

Note 4 - Stock options plan (Cont’d)

 

I.The Group used 0% as its expected dividend yield, based on historic policies and future plans.

 

II.The Parent-Company’s common stocks are quoted on the Over the Counter (“OTC”). However, the Group considers its share price as it is traded on OTC to not be an appropriate representation of fair value, since it is not traded on an active market. The Group determined that the market is inactive due to low level of activity of the Parent Company’s Common Stock, stale or non-current price quotes and price quotes that vary substantially either over time or among market makers. Consequently, the price of the Parent-Company’s Common Stock has been determined based on the April 2021 and July 2022 Private placement units of Common Stock and Warrants at a per unit purchase price of $0.64 and $0.88 respectively. In order to evaluate the price per share, the Warrant value has been deducted from the total unit price.

 

III.As the Company is at its early stage of operation, there is not sufficient historical volatility for the expected term of the stock options. Therefore, the Group uses an average historical share price volatility based on an analysis of reported data for a peer group of comparable publicly traded companies which were selected based upon industry similarities.

 

IV.The Group determined the risk-free interest rate by using a weighted-average equivalent to the expected term based on the U.S. Treasury yield curve in effect as of the date of grant.

 

V.The expected life of the granted options was determined based on the estimated behavior of the grantees; since most of the grantees are executives, the Company assumed that the large majority of the options will be exercised prior to their expiration.

 
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Stock options plan (Tables)
 3 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock-Based Compensation Expenses

   March 31, 2023   March 31, 2022 
   For the three-month period ended 
   March 31, 2023   March 31, 2022 
   US Dollars (In thousands) 
         
Research and development expenses   45    21 
Marketing expenses   159    - 
General and administrative expenses   274    32 
 Total stock based compensation   478    53 
Schedule of Stock Options, Valuation Assumptions

The following table sets forth information about the weighted-average fair value of options granted to employees and service providers during the three month periods ended March 31, 2023 and 2022, using the Black- Scholes-Merton option-pricing model and the weighted-average assumptions used for such grants:

  

   For the three-month period ended 
   March 31, 2023   March 31, 2022 
         
Dividend yields (see (I) below)   0.0%   0.0%
Share price (in U.S. dollar) (see (II) below)   0.53    0.26 
Expected volatility (see (III) below)   114.29% - 95.37%   82.77% - 142.57%
Risk-free interest rates (see (IV) below)   3.61% - 4%   0.18% - 1.7%
Expected life (in years) (see (V) below)   5 - 14.79    1.5 - 14.79 

 

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

 

Note 4 - Stock options plan (Cont’d)

 

I.The Group used 0% as its expected dividend yield, based on historic policies and future plans.

 

II.The Parent-Company’s common stocks are quoted on the Over the Counter (“OTC”). However, the Group considers its share price as it is traded on OTC to not be an appropriate representation of fair value, since it is not traded on an active market. The Group determined that the market is inactive due to low level of activity of the Parent Company’s Common Stock, stale or non-current price quotes and price quotes that vary substantially either over time or among market makers. Consequently, the price of the Parent-Company’s Common Stock has been determined based on the April 2021 and July 2022 Private placement units of Common Stock and Warrants at a per unit purchase price of $0.64 and $0.88 respectively. In order to evaluate the price per share, the Warrant value has been deducted from the total unit price.

 

III.As the Company is at its early stage of operation, there is not sufficient historical volatility for the expected term of the stock options. Therefore, the Group uses an average historical share price volatility based on an analysis of reported data for a peer group of comparable publicly traded companies which were selected based upon industry similarities.

 

IV.The Group determined the risk-free interest rate by using a weighted-average equivalent to the expected term based on the U.S. Treasury yield curve in effect as of the date of grant.

 

V.The expected life of the granted options was determined based on the estimated behavior of the grantees; since most of the grantees are executives, the Company assumed that the large majority of the options will be exercised prior to their expiration.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.1
General (Details Narrative) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]      
Net losses $ 1,350 $ 849  
Cash flow from operating activities net 900    
Accumulated deficit $ 11,280   $ 9,930
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Stock-Based Compensation Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
 Total stock based compensation $ 478 $ 53
Research and Development Expense [Member]    
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
 Total stock based compensation 45 21
Selling and Marketing Expense [Member]    
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
 Total stock based compensation 159
General and Administrative Expense [Member]    
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
 Total stock based compensation $ 274 $ 32
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Stock Options, Valuation Assumptions (Details) - $ / shares
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Jul. 31, 2022
Apr. 30, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Dividend yields [1] 0.00% 0.00%    
Share price [2] $ 0.53 $ 0.26    
Expected volatility minimum [3] 114.29% 82.77%    
Expected volatility maximum [3] 95.37% 142.57%    
Risk free interest rate minimum [4] 3.61% 0.18%    
Risk free interest rate maximum [4] 4.00% 1.70%    
Private Placement [Member] | Warrant [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Warrant exercise price per share     $ 0.88 $ 0.64
Minimum [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Expected life (in years) [5] 5 years 1 year 6 months    
Maximum [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Expected life (in years) [5] 14 years 9 months 14 days 14 years 9 months 14 days    
[1] The Group used 0% as its expected dividend yield, based on historic policies and future plans.
[2] The Parent-Company’s common stocks are quoted on the Over the Counter (“OTC”). However, the Group considers its share price as it is traded on OTC to not be an appropriate representation of fair value, since it is not traded on an active market. The Group determined that the market is inactive due to low level of activity of the Parent Company’s Common Stock, stale or non-current price quotes and price quotes that vary substantially either over time or among market makers. Consequently, the price of the Parent-Company’s Common Stock has been determined based on the April 2021 and July 2022 Private placement units of Common Stock and Warrants at a per unit purchase price of $0.64 and $0.88 respectively. In order to evaluate the price per share, the Warrant value has been deducted from the total unit price.
[3] As the Company is at its early stage of operation, there is not sufficient historical volatility for the expected term of the stock options. Therefore, the Group uses an average historical share price volatility based on an analysis of reported data for a peer group of comparable publicly traded companies which were selected based upon industry similarities.
[4] The Group determined the risk-free interest rate by using a weighted-average equivalent to the expected term based on the U.S. Treasury yield curve in effect as of the date of grant.
[5] The expected life of the granted options was determined based on the estimated behavior of the grantees; since most of the grantees are executives, the Company assumed that the large majority of the options will be exercised prior to their expiration.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Schedule of Stock Options, Valuation Assumptions (Details) (Parenthetical) - $ / shares
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Jul. 31, 2022
Apr. 30, 2021
Subsidiary, Sale of Stock [Line Items]        
Dividend rate [1] 0.00% 0.00%    
Private Placement [Member] | Warrant [Member]        
Subsidiary, Sale of Stock [Line Items]        
Warrant exercise price per share     $ 0.88 $ 0.64
[1] The Group used 0% as its expected dividend yield, based on historic policies and future plans.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Stock options plan (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Purchase plans employees 14,143,842  
Shares vested grant 9,494,372  
Share based compensation $ 478 $ 53
Minimum [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Warrants and rights outstanding term 3 years  
Maximum [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Warrants and rights outstanding term 10 years  
Common Stock [Member] | Minimum [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Warrants and rights outstanding term 1 year  
Common Stock [Member] | Maximum [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Warrants and rights outstanding term 3 years  
Employee Stock Option One [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Stock issued during period shares issued for services 8,687,842  
Shares issued price per share $ 0.32  
Employee Stock Option Two [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Stock issued during period shares issued for services 4,776,000  
Shares issued price per share $ 0.58  
Employee Stock Option Three [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Stock issued during period shares issued for services 480,000  
Shares issued price per share $ 0.01  
Employee Stock Option Four [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Stock issued during period shares issued for services 200,000  
Shares issued price per share $ 0.64  
XML 27 form10-q_htm.xml IDEA: XBRL DOCUMENT 0001839133 2023-01-01 2023-03-31 0001839133 2023-05-15 0001839133 2023-03-31 0001839133 2022-12-31 0001839133 2022-01-01 2022-03-31 0001839133 us-gaap:CommonStockMember 2022-12-31 0001839133 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001839133 us-gaap:RetainedEarningsMember 2022-12-31 0001839133 us-gaap:CommonStockMember 2021-12-31 0001839133 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001839133 us-gaap:RetainedEarningsMember 2021-12-31 0001839133 2021-12-31 0001839133 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001839133 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001839133 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001839133 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001839133 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001839133 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001839133 us-gaap:CommonStockMember 2023-03-31 0001839133 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001839133 us-gaap:RetainedEarningsMember 2023-03-31 0001839133 us-gaap:CommonStockMember 2022-03-31 0001839133 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001839133 us-gaap:RetainedEarningsMember 2022-03-31 0001839133 2022-03-31 0001839133 IRME:EmployeeStockOptionOneMember 2023-01-01 2023-03-31 0001839133 IRME:EmployeeStockOptionOneMember 2023-03-31 0001839133 IRME:EmployeeStockOptionTwoMember 2023-01-01 2023-03-31 0001839133 IRME:EmployeeStockOptionTwoMember 2023-03-31 0001839133 IRME:EmployeeStockOptionThreeMember 2023-01-01 2023-03-31 0001839133 IRME:EmployeeStockOptionThreeMember 2023-03-31 0001839133 IRME:EmployeeStockOptionFourMember 2023-01-01 2023-03-31 0001839133 IRME:EmployeeStockOptionFourMember 2023-03-31 0001839133 srt:MinimumMember us-gaap:CommonStockMember 2023-03-31 0001839133 srt:MaximumMember us-gaap:CommonStockMember 2023-03-31 0001839133 srt:MinimumMember 2023-03-31 0001839133 srt:MaximumMember 2023-03-31 0001839133 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001839133 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001839133 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-03-31 0001839133 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-03-31 0001839133 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-03-31 0001839133 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-03-31 0001839133 srt:MinimumMember 2023-01-01 2023-03-31 0001839133 srt:MaximumMember 2023-01-01 2023-03-31 0001839133 srt:MinimumMember 2022-01-01 2022-03-31 0001839133 srt:MaximumMember 2022-01-01 2022-03-31 0001839133 us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2021-04-30 0001839133 us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2022-07-31 iso4217:USD shares iso4217:USD shares pure iso4217:ILS utr:D 0001839133 false Q1 --12-31 http://fasb.org/us-gaap/2023#RelatedPartyMember http://fasb.org/us-gaap/2023#RelatedPartyMember P1Y P3Y 10-Q true 2023-03-31 2023 false 000-56492 IR-Med, Inc. NV 84-4516398 ZHR Industrial Zone Rosh Pina IL 972 4-655-5054 Yes Yes Non-accelerated Filer true true false false 68829424 2103000 3002000 56000 55000 2159000 3057000 11000 11000 136000 155000 67000 71000 214000 237000 2373000 3294000 468000 500000 159000 162000 627000 662000 26000 40000 653000 702000 0.001 0.001 250000000 250000000 68829424 68829424 68808970 68808970 68000 68000 12932000 12454000 -11280000 -9930000 1720000 2592000 2373000 3294000 605000 477000 172000 51000 575000 325000 -1352000 -853000 2000 4000 -1350000 -849000 -0.020 -0.013 68808970 68000 12454000 -9930000 2592000 20454 478000 478000 -1350000 -1350000 68829424 68000 12932000 -11280000 1720000 64601649 64000 7503000 -5196000 2371000 64601649 64000 7503000 -5196000 2371000 53000 53000 -849000 -849000 64601649 64000 7556000 -6045000 1575000 64601649 64000 7556000 -6045000 1575000 -1350000 -849000 478000 53000 4000 3000 6000 2000 1000 80000 -25000 121000 -900000 -754000 11000 9000 -20000 1000 -2000 -899000 -776000 3002000 2815000 2103000 2039000 160000 -160000 <p id="xdx_806_eus-gaap--NatureOfOperations_zFgaAEyewUv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 - <span id="xdx_82E_znVY4whOVJg1">General</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description of Business </b></span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IR-Med, Inc. (OTC QB: IRME, hereinafter: the “Parent Company”) was incorporated in Nevada in 2007 and is a holding company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registered office of IR-Med, Inc. and the corporate headquarters and research facility of IR. Med Ltd. are located in Rosh Pina, Israel.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is a development stage medical device company developing its technology through its Subsidiary and is utilizing Infra-Red light spectroscopy (IR) combined with Artificial Intelligence (AI) technology platform to develop non-invasive devices for various medical indications, by detecting and measuring various biomarkers and molecules in the blood and in human tissue in real-time. The initial product candidates which are currently in various stages of development are non-invasive, user friendly and designed to address the medical needs of large and growing target patient groups by offering earlier and more accurate information for detection, which is expected to reduce healthcare expenses and reducing the widespread reliance on antibiotics administration, and other interventional options optimizing the delivery of the targeted medical services and, as a result, improving the efficacy and safety of administered treatments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going Concern </b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is in its development stage and does not expect to generate significant revenue until such time as the Company shall have completed the design and development of its initial product candidate and obtained the requisite approvals to market the product. During the three months ended March 31, 2023, the Company has incurred losses of US$<span id="xdx_907_eus-gaap--NetIncomeLoss_iN_pn3n3_di_c20230101__20230331_znF1IMLDMjBe" title="Net losses">1,350</span> thousand and had a negative cash flow from operating activities of US$ <span id="xdx_90F_ecustom--NetCashFlowsProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20230101__20230331_zRaRT8T5WVt8" title="Cash flow from operating activities net">900</span> thousand. The accumulated deficit as of March 31, 2023 is US$ <span id="xdx_909_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20230331_zZXMaKuHSCzi" title="Accumulated deficit">11,280</span> thousand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management’s plans regarding these matters include continued development and marketing of its products, as well as seeking additional financing arrangements. Although management continues to pursue these plans, there is no assurance that the Company will be successful in raising the needed capital from revenues or financing on commercially acceptable terms. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Management’s plans regarding these matters include continued development and marketing of its products, as well as seeking additional financing arrangements. As a result of the Company’s financial condition, substantial doubt exists that the Company will be able to continue as a going concern for one year from the issuance date of this first quarter of 2023 Report.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IR-Med Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to the Interim Unaudited Condensed Consolidated Financial Statements</b></span></p> <div style="font-family: Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font: 1pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> -1350000 -900000 -11280000 <p id="xdx_805_eus-gaap--QuarterlyFinancialInformationTextBlock_zQrUtFEPnug3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 - <span id="xdx_826_zk6uB9oLD7G9">Interim Unaudited Financial Information</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“U.S GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and therefore should be read in conjunction with the Company’s Annual Report on for the year ended December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 425.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the opinion of management, all adjustments considered necessary for a fair statement, consisting of normal recurring adjustments, have been included. Operating results for the three month period ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Use of Estimates</span>:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant items subject to such estimates and assumptions including fair value of warrants and the share-based compensation. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_80F_eus-gaap--SignificantAccountingPoliciesTextBlock_zMWkN5V3ReP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 3 - <span id="xdx_820_zoAq9Sj6YTz">Significant Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These interim unaudited condensed consolidated financial statements have been prepared according to the same accounting policies as those discussed in the Company’s Annual Report for the year ended December 31, 2022. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_805_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zZ01UzJ9zqLl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4 - <span id="xdx_82B_zjjHqWFe5XSe">Stock options plan</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 23, 2020 the Group’s board of directors approved and the shareholders adopted a share-based compensation plan (“2020 Incentive Stock Plan”) for future grants by the Parent Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2023, the Parent Company awarded to its employees and service providers options to purchase up to <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c20230101__20230331_zNJgQbuevm7h" title="Purchase plans employees">14,143,842</span> shares of Common Stock, of which options for <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20230101__20230331__us-gaap--AwardTypeAxis__custom--EmployeeStockOptionOneMember_zXwx7bebhAsi" title="Stock issued during period shares issued for services">8,687,842</span> shares were at an exercise price of US$ <span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20230331__us-gaap--AwardTypeAxis__custom--EmployeeStockOptionOneMember_zjaxfuAOCnKa" title="Shares issued price per share">0.32</span> per share, options for <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230331__us-gaap--AwardTypeAxis__custom--EmployeeStockOptionTwoMember_zDRkR6YV0mrj" title="Stock issued during period shares issued for services">4,776,000</span> shares were at an exercise price of US$ <span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_c20230331__us-gaap--AwardTypeAxis__custom--EmployeeStockOptionTwoMember_zFMg2YMAa6E4" title="Shares issued price per share">0.58</span> per share, options for <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230331__us-gaap--AwardTypeAxis__custom--EmployeeStockOptionThreeMember_zYtIZsnz1mza" title="Stock issued during period shares issued for services">480,000</span> shares were at an exercise price of US$ <span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_c20230331__us-gaap--AwardTypeAxis__custom--EmployeeStockOptionThreeMember_zjNGa1CARCol" title="Shares issued price per share">0.01</span> per share and options for <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230331__us-gaap--AwardTypeAxis__custom--EmployeeStockOptionFourMember_zs4jdnDvc0Ug" title="Stock issued during period shares issued for services">200,000</span> shares</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IR-Med Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to the Interim Unaudited Condensed Consolidated Financial Statements</b></span></p> <div style="font-family: Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font: 1pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4 - Stock options plan (Cont’d)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">were at an exercise price of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20230331__us-gaap--AwardTypeAxis__custom--EmployeeStockOptionFourMember_zJgbOMmjmnV3" title="Shares issued price per share">0.64</span> per share. As of March 31, 2023 options for <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20230101__20230331_zZkSNGsrpCVh" title="Shares vested grant">9,494,372</span> shares were vested and the remaining balance has a vesting period ranging between <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_zTTGZ16r1er8" title="Warrants and rights outstanding term::XDX::P1Y"><span style="-sec-ix-hidden: xdx2ixbrl0312">one</span></span> to <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_zEsQE1RL8VTc" title="Warrants and rights outstanding term">three years</span>. The options are exercisable for periods ranging between <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20230331__srt--RangeAxis__srt--MinimumMember_zN1xXyQhQrM3" title="Warrants and rights outstanding term::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0316">three</span></span> to <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20230331__srt--RangeAxis__srt--MaximumMember_zmE31Zgds08i" title="Warrants and rights outstanding term">ten years</span> from the vesting date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The grant was approved following the adoption of the 2020 incentive stock plan (hereinafter the “Plan”) by the Parent Company on December 23, 2020 and the adoption of the sub plan (the “Israeli appendix”) on April 29, 2021. The Group recorded in the statement of operations a non-cash expense of $<span id="xdx_904_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20230331_zsDwCLvsBn46" title="Share based compensation">478</span> thousands and $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pn3n3_c20220101__20220331_z1GR6SzuWJGl">53</span> thousands during the three months ended March 31, 2023 and 2022 respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The stock-based compensation expenses for the three months ended March 31, 2023 and 2022 were recognized in the statements of operations as follows;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p id="xdx_89F_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ztrYmZBytxJi" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><span id="xdx_8BF_z9gORjCl0bEd" style="display: none">Schedule of Stock-Based Compensation Expenses</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_491_20230101__20230331_zRUA92sJkOYk" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">March 31, 2023</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_491_20220101__20220331_zagBBxkyNW2k" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">March 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For the three-month period ended</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">March 31, 2023</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">March 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">US Dollars (In thousands)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zagSQiLx6VS7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Research and development expenses</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zQsPp5O2u4Aa" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Marketing expenses</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">159</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0329">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z0tT4MoLFl98" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">General and administrative expenses</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">274</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">32</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_pn3n3_zSDcwTAFcQtl" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif"> Total stock based compensation</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">478</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">53</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A8_ziMF6UuvzXej" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 141.75pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zGOIU2a5YeT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth information about the weighted-average fair value of options granted to employees and service providers during the three month periods ended March 31, 2023 and 2022, using the Black- Scholes-Merton option-pricing model and the weighted-average assumptions used for such grants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  <span id="xdx_8BB_zyMnnUObSDqa" style="display: none">Schedule of Stock Options, Valuation Assumptions</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For the three-month period ended</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">March 31, 2023</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">March 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: justify"><span id="xdx_F44_zlmTEBuiH0B3" style="font-family: Times New Roman, Times, Serif">Dividend yields (see (I) below)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230331_fSS4___zcQ7F7l5IYm7" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Dividend yields"><span style="font-family: Times New Roman, Times, Serif">0.0</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220331_fSS4___zlOdECdbOaa6" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Dividend yields"><span style="font-family: Times New Roman, Times, Serif">0.0</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F4E_zvghSKYlMMZa" style="font-family: Times New Roman, Times, Serif">Share price (in U.S. dollar) (see (II) below)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--SharePrice_iI_pid_c20230331_fSUku_z5oKrlwZACFe" title="Share price">0.53</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--SharePrice_iI_pid_c20220331_fSUku_zpwwkj7fYAFd" title="Share price">0.26</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F4D_z2QX1pQksp56" style="font-family: Times New Roman, Times, Serif">Expected volatility (see (III) below)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20230331_fSUlJLg_____znq5xuj782O8" title="Expected volatility minimum">114.29</span>% - <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230101__20230331_fSUlJLg_____zvxhvnlXou1j" title="Expected volatility maximum">95.37</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20220101__20220331_fSUlJLg_____zWzFHZtleO7c" title="Expected volatility minimum">82.77</span>% - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20220101__20220331_fSUlJLg_____zykibwMiith" title="Expected volatility maximum">142.57</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F49_zlQbob6cV1R9" style="font-family: Times New Roman, Times, Serif">Risk-free interest rates (see (IV) below)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20230331_fSVYu_z4k7eIh42kq4" title="Risk free interest rate minimum">3.61</span>% - <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20230101__20230331_fSVYu_zwqMuq3jhleg" title="Risk free interest rate maximum">4</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20220331_fSVYu_zMWjfunuGwHi" title="Risk free interest rate minimum">0.18</span>% - <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20220101__20220331_fSVYu_zlRd313OPXq4" title="Risk free interest rate maximum">1.7</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F45_zyBqpota7iBb" style="font-family: Times New Roman, Times, Serif">Expected life (in years) (see (V) below)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230331__srt--RangeAxis__srt--MinimumMember_fVi4___z6t8nrDjd991" title="Expected life (in years)">5</span> - <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230331__srt--RangeAxis__srt--MaximumMember_fVi4___zPb71y4X6022" title="Expected life (in years)">14.79</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__srt--RangeAxis__srt--MinimumMember_fVi4___zXQr7cPdYGr" title="Expected life (in years)">1.5</span> - <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__srt--RangeAxis__srt--MaximumMember_fVi4___zD8mk8AV7D37" title="Expected life (in years)">14.79</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to the Interim Unaudited Condensed Consolidated Financial Statements</b></span></p> <div style="font-family: Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font: 1pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4 - Stock options plan (Cont’d)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F09_zmRmx8E8Zvzc">I.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F17_zxwlTRFHZVd1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Group used <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbnMsIFZhbHVhdGlvbiBBc3N1bXB0aW9ucyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_c20230101__20230331_zwFjLQ04SkW4" title="Dividend rate">0</span>% as its expected dividend yield, based on historic policies and future plans.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F0E_zNfxDVUFhBfk">II.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zZIeFNHsiAh6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Parent-Company’s common stocks are quoted on the Over the Counter (“OTC”). However, the Group considers its share price as it is traded on OTC to not be an appropriate representation of fair value, since it is not traded on an active market. The Group determined that the market is inactive due to low level of activity of the Parent Company’s Common Stock, stale or non-current price quotes and price quotes that vary substantially either over time or among market makers. Consequently, the price of the Parent-Company’s Common Stock has been determined based on the April 2021 and July 2022 Private placement units of Common Stock and Warrants at a per unit purchase price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210430__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA3d6oN63Oxj" title="Warrant exercise price per share">0.64</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbnMsIFZhbHVhdGlvbiBBc3N1bXB0aW9ucyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220731__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoWBVusIvwyf" title="Warrant exercise price per share">0.88</span> respectively. In order to evaluate the price per share, the Warrant value has been deducted from the total unit price.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F07_zK7Woc2Mq6k3">III.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zUQuZekOf1od" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As the Company is at its early stage of operation, there is not sufficient historical volatility for the expected term of the stock options. Therefore, the Group uses an average historical share price volatility based on an analysis of reported data for a peer group of comparable publicly traded companies which were selected based upon industry similarities.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F0C_z4XGQOgOiZ65">IV.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zVZey9JvCw5a" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Group determined the risk-free interest rate by using a weighted-average equivalent to the expected term based on the U.S. Treasury yield curve in effect as of the date of grant.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F01_zv6oXDenRhY6">V.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_z9yYT6DBNZcl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expected life of the granted options was determined based on the estimated behavior of the grantees; since most of the grantees are executives, the Company assumed that the large majority of the options will be exercised prior to their expiration.</span></td></tr></table> <p id="xdx_8A1_zD03CIxBrBH2" style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> 14143842 8687842 0.32 4776000 0.58 480000 0.01 200000 0.64 9494372 P3Y P10Y 478000 53000 <p id="xdx_89F_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ztrYmZBytxJi" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><span id="xdx_8BF_z9gORjCl0bEd" style="display: none">Schedule of Stock-Based Compensation Expenses</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_491_20230101__20230331_zRUA92sJkOYk" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">March 31, 2023</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_491_20220101__20220331_zagBBxkyNW2k" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">March 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For the three-month period ended</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">March 31, 2023</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">March 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">US Dollars (In thousands)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zagSQiLx6VS7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Research and development expenses</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zQsPp5O2u4Aa" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Marketing expenses</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">159</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0329">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z0tT4MoLFl98" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">General and administrative expenses</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">274</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">32</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_pn3n3_zSDcwTAFcQtl" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif"> Total stock based compensation</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">478</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">53</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 45000 21000 159000 274000 32000 478000 53000 <p id="xdx_89B_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zGOIU2a5YeT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth information about the weighted-average fair value of options granted to employees and service providers during the three month periods ended March 31, 2023 and 2022, using the Black- Scholes-Merton option-pricing model and the weighted-average assumptions used for such grants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  <span id="xdx_8BB_zyMnnUObSDqa" style="display: none">Schedule of Stock Options, Valuation Assumptions</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For the three-month period ended</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">March 31, 2023</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">March 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: justify"><span id="xdx_F44_zlmTEBuiH0B3" style="font-family: Times New Roman, Times, Serif">Dividend yields (see (I) below)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230331_fSS4___zcQ7F7l5IYm7" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Dividend yields"><span style="font-family: Times New Roman, Times, Serif">0.0</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220331_fSS4___zlOdECdbOaa6" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Dividend yields"><span style="font-family: Times New Roman, Times, Serif">0.0</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F4E_zvghSKYlMMZa" style="font-family: Times New Roman, Times, Serif">Share price (in U.S. dollar) (see (II) below)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--SharePrice_iI_pid_c20230331_fSUku_z5oKrlwZACFe" title="Share price">0.53</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--SharePrice_iI_pid_c20220331_fSUku_zpwwkj7fYAFd" title="Share price">0.26</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F4D_z2QX1pQksp56" style="font-family: Times New Roman, Times, Serif">Expected volatility (see (III) below)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20230331_fSUlJLg_____znq5xuj782O8" title="Expected volatility minimum">114.29</span>% - <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230101__20230331_fSUlJLg_____zvxhvnlXou1j" title="Expected volatility maximum">95.37</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20220101__20220331_fSUlJLg_____zWzFHZtleO7c" title="Expected volatility minimum">82.77</span>% - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20220101__20220331_fSUlJLg_____zykibwMiith" title="Expected volatility maximum">142.57</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F49_zlQbob6cV1R9" style="font-family: Times New Roman, Times, Serif">Risk-free interest rates (see (IV) below)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20230331_fSVYu_z4k7eIh42kq4" title="Risk free interest rate minimum">3.61</span>% - <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20230101__20230331_fSVYu_zwqMuq3jhleg" title="Risk free interest rate maximum">4</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20220331_fSVYu_zMWjfunuGwHi" title="Risk free interest rate minimum">0.18</span>% - <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20220101__20220331_fSVYu_zlRd313OPXq4" title="Risk free interest rate maximum">1.7</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F45_zyBqpota7iBb" style="font-family: Times New Roman, Times, Serif">Expected life (in years) (see (V) below)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230331__srt--RangeAxis__srt--MinimumMember_fVi4___z6t8nrDjd991" title="Expected life (in years)">5</span> - <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230331__srt--RangeAxis__srt--MaximumMember_fVi4___zPb71y4X6022" title="Expected life (in years)">14.79</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__srt--RangeAxis__srt--MinimumMember_fVi4___zXQr7cPdYGr" title="Expected life (in years)">1.5</span> - <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__srt--RangeAxis__srt--MaximumMember_fVi4___zD8mk8AV7D37" title="Expected life (in years)">14.79</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to the Interim Unaudited Condensed Consolidated Financial Statements</b></span></p> <div style="font-family: Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font: 1pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4 - Stock options plan (Cont’d)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F09_zmRmx8E8Zvzc">I.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F17_zxwlTRFHZVd1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Group used <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbnMsIFZhbHVhdGlvbiBBc3N1bXB0aW9ucyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_c20230101__20230331_zwFjLQ04SkW4" title="Dividend rate">0</span>% as its expected dividend yield, based on historic policies and future plans.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F0E_zNfxDVUFhBfk">II.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zZIeFNHsiAh6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Parent-Company’s common stocks are quoted on the Over the Counter (“OTC”). However, the Group considers its share price as it is traded on OTC to not be an appropriate representation of fair value, since it is not traded on an active market. The Group determined that the market is inactive due to low level of activity of the Parent Company’s Common Stock, stale or non-current price quotes and price quotes that vary substantially either over time or among market makers. Consequently, the price of the Parent-Company’s Common Stock has been determined based on the April 2021 and July 2022 Private placement units of Common Stock and Warrants at a per unit purchase price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210430__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA3d6oN63Oxj" title="Warrant exercise price per share">0.64</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbnMsIFZhbHVhdGlvbiBBc3N1bXB0aW9ucyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220731__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoWBVusIvwyf" title="Warrant exercise price per share">0.88</span> respectively. In order to evaluate the price per share, the Warrant value has been deducted from the total unit price.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F07_zK7Woc2Mq6k3">III.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zUQuZekOf1od" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As the Company is at its early stage of operation, there is not sufficient historical volatility for the expected term of the stock options. Therefore, the Group uses an average historical share price volatility based on an analysis of reported data for a peer group of comparable publicly traded companies which were selected based upon industry similarities.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F0C_z4XGQOgOiZ65">IV.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zVZey9JvCw5a" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Group determined the risk-free interest rate by using a weighted-average equivalent to the expected term based on the U.S. Treasury yield curve in effect as of the date of grant.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F01_zv6oXDenRhY6">V.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_z9yYT6DBNZcl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expected life of the granted options was determined based on the estimated behavior of the grantees; since most of the grantees are executives, the Company assumed that the large majority of the options will be exercised prior to their expiration.</span></td></tr></table> 0.000 0.000 0.53 0.26 1.1429 0.9537 0.8277 1.4257 0.0361 0.04 0.0018 0.017 P5Y P14Y9M14D P1Y6M P14Y9M14D 0 0.64 0.88 Represents an amount less than US$ 1 thousand The Group used 0% as its expected dividend yield, based on historic policies and future plans. The Parent-Company’s common stocks are quoted on the Over the Counter (“OTC”). However, the Group considers its share price as it is traded on OTC to not be an appropriate representation of fair value, since it is not traded on an active market. The Group determined that the market is inactive due to low level of activity of the Parent Company’s Common Stock, stale or non-current price quotes and price quotes that vary substantially either over time or among market makers. Consequently, the price of the Parent-Company’s Common Stock has been determined based on the April 2021 and July 2022 Private placement units of Common Stock and Warrants at a per unit purchase price of $0.64 and $0.88 respectively. In order to evaluate the price per share, the Warrant value has been deducted from the total unit price. As the Company is at its early stage of operation, there is not sufficient historical volatility for the expected term of the stock options. Therefore, the Group uses an average historical share price volatility based on an analysis of reported data for a peer group of comparable publicly traded companies which were selected based upon industry similarities. The Group determined the risk-free interest rate by using a weighted-average equivalent to the expected term based on the U.S. Treasury yield curve in effect as of the date of grant. The expected life of the granted options was determined based on the estimated behavior of the grantees; since most of the grantees are executives, the Company assumed that the large majority of the options will be exercised prior to their expiration. EXCEL 28 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( %EJKU8'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !9:J]6U<,!2^\ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M3L,P#(=?!>7>NFDUAJ*N%Q GD)"8!.(6)=X6K?FCQ*C=VY.6K1."!^ 8^Y?/ MGR6W*@CE([Y$'S"2P70SVMXEH<*&'8B" $CJ@%:F,B=<;NY\M)+R,^XA2'64 M>X2ZJF[!(DDM2<($+,)"9%VKE5 1)?EXQFNUX,-G[&>85H ]6G24@)<<6#=- M#*>Q;^$*F&"$T:;O NJ%.%?_Q,X=8.?DF,R2&H:A')HYEW?@\/[\]#JO6QB7 M2#J%^5Q:^'47W1=02P,$% @ 66JO5IE&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" !9:J]6B;^.?%D% W' & 'AL+W=OII^E%\=-49#J6&5%B"_(FOL5CHM6-B41ZE?+(GH_"TX=D2B40$QEIP^/,LAB))K!.4X\?2 MM%&^TPK7CU?NESD\P#QR+88R^3L.373:Z#5(*"9\GIBQ7'P22Z".]0MDHO/_ MR:)XMN,U2##71J9+,90@C;/B+W]95L2:H-O>(&!+ 7LGH/X&@;\4^#EH4;(< MZR,W?'"BY((H^S2XV8.\;G(UT,29;<9[H^!N##HS&,IGH4B3Z(@KH4]:!CSM MG5:PU)\7>K9![Y-KF9E(DXLL%.%;?0O*4A:(K0ITSE##:ZX.B4\/"/.8[RC/ M<)O\E=".2_VF-'Y9/7YNYZ/5\\_9HS8*>MR_K@HJ'-IN!SL,C_6,!^*T >-, M"_4L&H/??Z-=[P\7W2\R>P/;+F';F/O@HPSF,$(->7B="1\\Z%A*IJ M(G5*I Y:IC/@"7.FRX1/74RX?L(3[:J*(2JK"=4MH;J[M=/=G"LC5/)*QF(F ME7'QX59&S9UXJ*HFWE&)=[1C-U0SB&'.Y63Y<;9$M77Y.R7G/W=."]C'?!DA7L)EYTK#>YV1UU\J*8F M'_6JQ=/[*<)O@JO-?%O,-C4A+JO+N!80*%JLX5RI]XA8C]UBUVQ2UO2=;8DK MZX*R"I2A);O(3&Q>@3,1Y&:>/@KEQ,--/,]K=KKM/G,"HMJZ@%66H6AZ6 &. MQ32V<0;:](:G[C;$C4;CYK4(#SZ,LN#0R;F/%$.K&$/Q(++D'$*O5=!C1Y!, M7\A?XM5)BEM!<]*>WZ>^>V3N(]K0*MM0/)PL.1_X"QF% !M/XH#GRR72?7'+ M7KO9[M"NW^\Y>?>1>F@5>R@>5I:\T.ND@CB0HQZ0>P,3$9&*#.4<&AS:78;N M3HV[WWQU(N\C"=$J"E$\ORR1S\(0W/7!ZH!@]Y4TM&?0(1[D(G-6$&XWECK*:^@VSK@3 M=Q^ABE:IBN)!Z'^X1;]WDN).HRLGWCXR%:LR%<-C4-YZ9TKPC0-YBT'_R+GX MXJJZ6%6,8GCNN9)Y!(Y@""'3\Q:3=K/;Z30[7J?M)-Q'?F)5?F([Y:=57BQ^ MLL79-)^AW8EXB^,WYQ>I(:ZJRUG%*+93C!IE\-.[^ IILS!?@3LY<<=-G/N( M4:R*46RG&&7S,"RNL,A.I7N6V>)S([,F#P(!-F 2%H9.WGW$*5;%*;93G+I/ M>9*0\[F&V]K=:W&?3=]4<%E=O"H]L9W2TT4JU-2.RC_!P40PR:8SGKG;M=ZW M(UQ6E[.*3&Q+9+([!-#-;J2!!$"^:$%,),C%BQ'V$_7Z5Z7B@X03O>9G)5Q7 ME[U*0FRG)'0?">C"6,OB-IOQ]I%\6)5\V$[)!\!2:+U[(X,GR/_YS@7Y/#?: M\"R$KNTD_D6A9ED/A5LG=[,[9<^#;J_'^FT&"_/S.F-K;6O&CKQ\QTJ3P&:V M8I>FO%KNBIWE>T&MZO%B2^V:VX&K22(F(/4.C^#UJMBE*DZ,G.4;/8_2&)GF MAY'@H5#V ;@_D=*L3NP+RKW"P7]02P,$% @ 66JO5E&U.$[_! E!0 M !@ !X;"]W;W)KZ<[Z5[0 G>?3>(2BR3.V@Y=[M??."E)6SNA2/T C9.9\3/C\3P> M7ZZ%?%8I8QK]S+-"78U2KB/KC5!<*2WRC3(@R'G1_-*? MFT!L*>"@1X%L%,BA"OY&P:\=;9#5;GVCFBXNI5@C::3!FGFH8U-K@S>\,,MX MIR5\Y:"G%TM1)+ H+$'PI$3&$ZIA<$,S6L0,W1G#"GUY*&B5('N4U$I6B3J:!_:CX"\W =Z?7C:FH M-F6JPLN"8 _6ZV7;&UO(]SS2"NV@#%J4P2#*ZS@6%8""^QDBX M-748[:%SB(1N;&&++1S$=B\TS6"#OI%\#YXMY'OAU TP:@%&@]G\ MERA.#\ 7'3.ECV1LQ]]IZ^]T<$'^$,43TDSFD"U*2QZ;,I:P4BBN78Y/K9AC MO+H8,Z(SBT$T70/I"TR[8DH]CH"\P[8B06D M^_O9OC&UNQV#/9 N(;]G-^(MGL4'P!R AEVS[I=9AY1/YD$/N([Y\&'4EW'Z MR#.N.7-C/"H!'LO:KL\=!>)A#KR7-&%U:@N=,HE*^FH8QNVX;X4]B&;[:V,+ MA9[7LS0=!^)A$KS3(GY.198PJ3Y_FA$\O4"9H(4;ITUT-MNXA*(>JL8='^*/ M$.)[B60S7D3VBX5+J!=G1XOX?5X\%.51R?%8UG;][N@1'\J/#?6\^?[J]-RF M/K)/. Z9H"_;.W[$PP399-%[ZV)S711:E=(6FO8=2'''B'@^F#VNW?@+,&-/ M& ?Y]<,)="1KN\U1Q[-DF&>7(L^A[ZXC,(9J*1'T#!5#)]Z9YV$$)P6D4BH9 M]&.A-_:\YJ]YIQ"M="HD_X\E9T""YL@#W5^3[TWPURIBB5C<^HK67TGD+V>.9LWF]:M$CXLLQNXCOG) M,/-?)] Y4)Z?0-,>TY)#H3I@VPV,R]\D^4I=8$/:<5C]^EY8V5[^E.,R$@NQ+47">4_A(!V-DV$:MPI;G<[J8PX$=B=N'Q$=4HXCXF3KRLC&PO=V]R:W-H965T M&ULK59=3]LP%/TK5C9-()4F3;^@:R-! 6W2V"HJM@>T!S>Y M;2P<.[.=%O;K=^V$J&5I!]+ZT/CCGN-SC^W@4P)#'C L]\5)C\I'O MZSB%C.JVS$'@S%*JC!KLJI6O;B=?QG@=NV2HU=L"/QCE=P1S,73Y3V/-KEH1E(#23@BA83KSS MSF@ZM/$NX#N#C=YJ$YO)0LH'V_F<3+S "@(.L;$,%!]KF +GE@AE_*HXO7I) M"]QN/[-?N]PQEP75,)7\!TM,.O%./9+ DA;7'Y(2\)S[1*8[JL6]0DV7VXVK]BW+]<,_Z-U2U2;?3 M(F$0=AO@T\/P2XAK>+@+]]&)VHZPMB-T?-T]?'.#Z>,A-40NR343: *CG,RD M9N[4W9\OM%%X]GXVI5IR]YJY[7T_0-MU>1+XPN&&?FJ46FA;*;WB*WP-T!H2(A7Z5051?/A'DBUKU" MD_NK1V/O^8(#N1)%!HI:\QHM.ZRCT".'%LFI(FO*"VC*N"0:.B+[CEU'03L(.F-_O9W+OZ)V5/9K ME?TWJ"RO+*&%2:5BOR%I4EL2]K=TA/V@_+U0_)K('=6#6O7@[:J9UD6SXL%? M.@:GI^%9+^R]$-P8&)R>#??H'=9ZAV_7BP54&[PT3*R:1 ]?*[HQL$FTOU43 M;#W&%^V*"4TX+!$:M(?(HU EHXIXK[41!,_8HRX65S-W:MLKG< M&LX$7"NBMU5%U8\E<+E?>*'W-'##-J6Q WXVK^D&;L'WZK4K *A&92 M$ 7KA7<97JS"P#HXB[\9[/51F]A0[J5\L)TOQ<(++!%PR(V5H/C9P0HXMTK( M\?]!U&OGM(['[2?U*Q<\!G-/-:PD_X<5IEQX,X\4L*9;;F[D_C,< DJL7BZY M=K]D?[ -/))OM9'5P1D)*B::+WT\).+( 76&':*#0]1UF+SB$!\<8A=H0^;" M^D -S>9*[HFRUJAF&RXWSANC8<(NXZU1^"]#/Y.MI"AP4: @V-*2LX(:[-P: M_.!J&4WDFOQ5@Z(VZYJTK>$B;(]U)N-16%GOL& MR:R^GQ\HE@U%] I%3+Y)84I-/B)-\=+?QXC:L**GL);1J. WJLY('+XC41#% M SRK7W>/1G#B-LNQTXM?T?LB TPNWOL!3@*.^V#I-U,]FWB M*!FF35O:=)3VNS3(*IM+ _/)I1[$2_NYC)-N,OM&LR0>YINU?+-1OBLFJ,@9 M,C)W+M\1 68(<-:;^WT7;\!D,DQWWM*=C])]Q6P1K,_$E$ PATP60VSGO1. MR0LZ='VCV>1\&"\,GBM&, JXI)KES8EF?.LVH5UARTHPG1469RQ;^0,YP:)0 M2,ZITJ>#-:&9)SU.7G 6=%/\BEG8W07^416L0&W-7A';!A600YKE S.4EQXU3P4FHZ1M:NU]])@Y7;-$A]7 MH*P!_K^6TCQU[ 3M4"K0CSA*^%@)A%C?J2I?!#0F_):M:0)?EBR-B8!NNE+Y.J7$SY3B2-4U MS59C$B;*9)2-/::3$=N(*$SH8XKX)HY)^O.!1FPW5K"R'W@*5X&0 ^IDM"8K M^DS%R_HQA9Y:HOAA3!,>L@2E=#E6[O&=AVVID$G\'=(=/VHC& L6\>P7[0I934&+#14\#&"06C4#!J"H9]0L$L%,RZ2\X)!:M0L"YUR2X4LLE4<[(RIF=$ MD,DH93N42FE DXULNC)M(#A,9&8]BQ2^AJ G)E.6^) GU$?0XBP*?2*@\RS@ M#Q)(<,26:!J09$4Y"A/XP!9O 8M\FO+?T?S[)A0_T8>7A&S\$!0_H@%Z>9ZA M#S)ST>J '>E4751N/:0NZ:?="V.66$1??M"XU>:_ML",^N& MN??!,TAB$J%'$OH#<&I*UJ& ?@?HO!OTB0JH6B!J3M(D3%:\"\OKQOK*P)>J MF@JS6$ZE7DZEGN&8)W >Z"I,I#-0:A%)%O03VI)H0Q$1:$87M\C GY"NZ;AM M*G)H.X.6J]%V8ILC=7M,Z=IN?K?\359T+$"RSNGZ98JD]]^Q;;V M1UMJ]0GF]016H=PL*3<[*?^+<8Y@=T,BH&A-TY#Y;2QW@K2[B-KJO">>7,;OAH&-9M05JWA0:V)IIU7*D M*84MQVJ/UBFC=:Y=QLY&[5RZC'6:OG89ZQ/,ZPFL0KE;4N[VLG&VXVTT0WK5I>SIM2@^'0T&HIUY32K:'>GG+#,O[A_]DY6\,>-E/.=35WZ-0< MGG6:OC;E^@3S>@*K4(ZUP[E;ZVTOZ(:Z?#.8GO'I&VX_7VN-R3:=6I+/^_+1 M.V.M2O?1-0>_B^Y]TK?2CIO%IC4*=]9M^=H4[Q7-ZPNMROKA1H*[KR07'A"[ M4:XX[/0%-"^ *JLQ-JSZ:GQ6K,K;X2J#+[K+U#=_HY4\X_P.U"*#]:&AUVNX M*3; 6'<;8;? .?JIJ ^W"=Q]G3AS]&F/OGE.AXU('YIZHTS?<7WH*-,^T;R^ MT*K$RVM)=>1PY,;=9V[8"9YH9DL^ 9$$D9AM$O%+1*&@10 #+\\W"$,S?]YI MI6*:;K*W@\YK+X E%_KR]'\C?(!WTVSI[S:^#VV[KS\;;#QQ=X_:ZH' M$_FC**0.'.LXBN@2S&FW#N1(FK\SYAW!UMF[V"L3@L59,Z#$IZD4@.]+QL2^ M(PV4K[V3_P!02P,$% @ 66JO5C_!51$3!0 <10 !@ !X;"]W;W)K MPL[9)VF]_8T,@"89KJTA5 V0\>6]F/&_P9"?DLUI3JM%+EG(U M]=9:;ZY]7\5KFA%U)3:4PS=+(3.BX5:N?+61E"1V49;Z. @&?D88]V83^^Q! MSB8BURGC]$$BE6<9D:^W-!6[J1=Z^P<_V&JMS0-_-MF0%7VD^FGS(.'.K[PD M+*-<,<&1I,NI=Q->SS$V"ZS%WXSNU,$U,E060CR;FV_)U L,(IK26!L7!#ZV M=$[3U'@"'#]+IU[UFV;AX?7>^U=+'L@LB*)SD?[#$KV>>B,/)71)\E3_$+L_ M:$FH;_S%(E7V/]J5MH&'XEQID96+ 4'&>/%)7LI '"P /^X%N%R 3Q?T6A9$ MY8+($BV065IW1)/91(H=DL8:O)D+&QN[&M@P;M+XJ"5\RV"=GLT%3R I-$%P MI43*$J+AYE'#!V1+*R26:$[4&GV%C"MT\<1)GC"P^8PNT=/C';KX]!E]0HRC MO]8B5X0G:N)K0&;\^W&)XK9 @5M01.A><+U6Z N@28[7^\"HHH7WM&YQI\-[ M(J]0%/Z&<( C!Y[YVY?C#CA1%>7(^HO:HFP"N+0!7$J1(=B%DFC&5T49,\VH M,VJ%UY[;J]GAUVI#8CKU8 LK*K?4F_WZ2S@(?G=1/I.SHP#TJ@#TNKS/_A0* MJ N)])HB(,]$XN);.!E8)Z8!;6>78=0/)O[VD(C#:M0;5T9' /L5P'YGAFZ2 M?V&S%16O!32H6/"8I12E3>3&@$.'C2&K+A;]L/12>*:-OW(G;9AA7#8B?". NV8M:(:-E&= M8&I:M$ :59!&G9!NXECF$+ EXP1*B*30&R%XU 5OU/CQR\$)/H<)=@,<5P#' MG0"_\1@$7U'3LTD37(W<(3. +8/P'O, IQV(+^0%K#3O3?RQZ! MTX"+5> MAYUJ.'O(9;PVU0;3ST::O.E76W#T9\XV1B:<(?B Q"(G^\BQX=KJL=;@L%N$ M#[=0*B"AFLH,9MZ-4,S-I]/?>_CT' 7=0J=6[+!3^YK;Z\V5^@%-==/J.WI+ M6].K13?L5MTORR6\XYC*HR]0A'Q%$70-BHIK&,AY0=N4H[TP-;DEJ9E=G'2; MLGO:O!TF;2H3UM(<=FNSR<^^?YOTO ]T4Y*WC8+>'S M-J2(P)^VH^""KACGIM@@4=U3;=C4\"@(\"F7IA4>A?T6+K78A]UJ_Q8NU"CI M_[)H*CP.@^B4A<,JB%KV.JX' 1QTBM)WP2\M 9!^&$+M$8"Z=L'$G1/%>V7H M7-Z.:=<3!.Z>(%KF'VZBD4L):80L*JI+J39O+3(I:U*: PS[^@[]L31S!JP3 MPCNZ(6[.(Q"(ELS7XPCN5/IZ6KU(#F)Q%(*4D05+;;MWQ&'_[:N]L:[(2M+B M=,,9D ^,'NZ 8,?K;",B_L'A34;ERIYI*63G\N+ HWI:G9O=V-.BD^>WX?6\ M./VJW12'1(%N=;Q8T6&WM$M!!:B\Q>KBG,V-(8P/=+ M(?3^QOQ ==7=#%;*;N*XDV^1994)3F7 M5=4J4:1X]V%K'\!!DX,U!A@#&-+RU^)OMO6C3L(O&.PJ\/AM?+$XN7\C\/.'?AG?QX#]))"OO/\C+E3X;SP40 M6ZZ2>%!X;/D=6RN. .-C[W.\7U(,#_\/WG_,L2.6E8K\SMO_&)WJL_&;,6E> MJ\ZF6[_[)_?QO!1_E;& @:X\I3?>IY^"L&R]Y@F7&7 MA3+*[U52YZ?![RC(;'B3/SG4; UPQDE2[E+ 5P.[=/X3.P[*GLX2G,G0K.H- M+XOA\BN&QW3M7:HC_> TZR_M9P"Q1[(T=_7IY@M'K'R9411X M8R(6@ZE?KTW%DLD>(&6 8B] ]HL H](?.Q5@%O-G84&%JJ:UJHPUZ;XXF1*\ MT+^2AI/ 9'TU0+SUL:8;Q(DU8E!L"Y@^N@)7\Q:*UTH944S0-VI8FPKEA2\" MM(]CF"BA&51GZX M?FM5$MFGY >4Y+P[,FZK(K2TCR02)M%6!>.[.$0Y,DZ>4CQQ0BL),XD0 Z[@ M;UC%+LC;8+-PK")L6-YQW9DCQ(V MBYP(C)@DT;7!ZZY*HPIFTOKPMJL-$BWYK+H@-6GOQ<& (F^H74P[+0M&=$":#;"53P49C3S(B MD65-\>%A&P LB;0X&4?X/NM(S,^FE"VFC33\;CGDCI,E"Q6L][2)/N4:@V>X ME\X"M=AR)V0:Y'<[@&5I?U659$2UYM+& \ L$0FQI"SLT]'EE'[R,$;7(J[@ M_MC!* KINS^W<4ZV!R+G4T^M$+O)PHF,2!E(>X$F0 4#*-$.-""6#OF0*I4X M!/.P7*R5M52K;5$%*PR,9$(IJKZ^'H @+L'VAS*G?9F7-*R2RCTOC@)_[$PT M\JD5UI2- CIW7,HS>B>0_=*7.1MU8!XU99]GV>?I.@OEL$U/O@BC+FHN?04I M\C&63GI_]P]:3(Y?SNF[^9P6B\GRS1Q^',B4:&0S6+Q^&T>0&Q0(%%T%W2.( MZ!^5LE##L>VT$ 0NP>F7C.3&R,&(9<]/'U+,=;.#SLDS,G_(*J2UZ6MS779^ M&0Q!N0(+)7*!%LD"W.S![I?/]+5=$ $J0#/\3 B:RDAY8#F(7&Z;5*OT!5<[ M S@KEII =<=U9[..*22I)U\$ V50J=8D 1E\,]03: T'J-&3*)N&@TBZR!%< MMDFM+-;ET,0BBNO]^28^G&^TSV4\D"O(E/X_CIWEB M7!I7MB/I(JFXA*WYS]FEORV[H[\GNW3QH"6#^AP<3S+F!\J JSB<(&,X$HH& M8I/3OEN)"$!@XM=S7#+A]\$5&=OXJ%Z; M$!/U1QB,CJ05Z99QOD'_EM-/.9W)L2Z.L+0XD[T^F(;>.]4A&' ,Z=.B_?K@ M>(R71T_"CQU99P?W#I3?)M^N(F*"WI4KR'YT?X&[*/>6A^GE]@==V1@4B.4U M3.?3UR_'%,J-JKPDW^9;S,HGW(GR7SG(<9 )^+[VB+5_D07VU]KSWP%02P,$ M% @ 66JO5@G X.M]! 5 H !@ !X;"]W;W)K#TNA3+:8Q6E M<+M+U'8[S\99^^!6;8K #X:+624V>(?AOKIQ=#?L4*0JT7AE#3A2'0^O M6_3/43MI60F/5U;_I60HYME9!A+7HM;AUFY_P4;/*>/E5OOX"]MD>WJ205[[ M8,O&F1B4RJ1_\=SDX<#A;/2"PZ1QF$3>*5!D^5$$L9@YNP7'UH3&%U%J]"9R MRG!1[H*CMXK\PN+:!'2JA'LC:JD"2OBLC#"Y$AJN32HZ96\V#!2,789Y WR9 M@"493 MX]$]8;9X^V;\?G3QBHB33L3):^C_IWRO A^G_:L-V)O ._B/8>&/ GLBSVU9 M";-39@-UY[#N''P0 6G.@P>[AE @7"4'*,03P@K1 '&HA",WQ8.<6R?)&6E6 M0@'W@[L!;-"@$YJJ2:^QX@AL5YO 82NG*%:ET?=^>OOF;#(979 7?%DN;^+M M^.)G(-:$GG3MR:F]F@$L8V0"U+L^$]V!M&!L(*MVQ MD:V487C26 I#2YN9]:-L(1]H6R6FQ,0KB5PO0UC>T[J/ @6LA7)[4?UDZF.1 M"-1PRC0IRFOG^-D!:C^V0R^V0Y-O.8#?*BI[=*=)L$J*UB#5NFBGI(&:ERP=^+MIPM>BA$(.T[X@'X7-&WA7OYAQPR MG1^3.!W O<<>P7TBN=08U D\'JFS4Y_0RZ.53\7E?E)AUS5]ZINFF_Q!02!8 MNGM$>*CEILD==D&YC82GCW#%,9.BGEBO24JCE%N#YZ?D\8E#2?;8=*!68J6T M"JJ!DMV:C);$DZO!+%YR2F$DD6F3RTU@M>)'LG1U4-4;>F26N*['/4.IUPX#./9Y M&!Y\Z4MTFWB>B6@FI(]^][0[,BW326%OGLY;- 8;1=HTKLEU-/APFH%+9YAT M$VP5SPTK&^@4$B\+6C7HV(#>\T9K;SA =Y!<_ M02P,$% @ 66JO5N8& M,BF, @ QP4 !@ !X;"]W;W)K]7$"[0TQ8[=OJ!-C&0M!NV0X>@W<=AV$&QF5BH)7D2W;3_?I3L>!F09L N M,4GQ/3Y&(J=;8Q]=A4CPK&KM9E%%U%S%L2LJ5,*-3(.:3];&*D'LVDWL&HNB M#"!5QVF2G,=*2!WETQ!;VGQJ6JJEQJ4%URHE[,L":[.=1>-H%[B7FXI\(,ZG MC=C@ ]+79FG9BP>64BK43AH-%M>S:#Z^6DQ\?DCX)G'K]FSPG:R,>?3.IW(6 M)5X0UEB09Q#\><(;K&M/Q#)^]9S14-(#]^T=^X?0._>R$@YO3/U=EE3-HLL( M2ER+MJ9[L_V(?3]GGJ\PM0N_L.URLS2"HG5D5 ]F!4KJ[BN>^_]A#W"9O )( M>T :='>%@LI;02*?6K,%Z[.9S1NAU8!F<5+[2WD@RZ>2<90_R(V6:UD(33 O M"M-JDGH#2U/+0J*;QL1%?&I<](2+CC!]A3"#.Z.IEUC^C8]9W* PW2E< MI$<)[X0=039^"VF29D?XLJ'C+/!EK_ =Z!)^S%>.++^0GX<:[O@FA_G\U%RY M1A0XBW@L'-HGC/+3D_%Y';UJZS'&>7PH?74@M=2%&#(P[P,).#2CPAK! UL(!& M6,X37,J6OA(9H K!"84AV@MH=@*$XW/C$$KI>#RX(JL)D!NC&J%?3D\NT_'% MM8.YUBT7OL?&6 )>7R'K!84%]$\3;K% M4*[>USI" Y=6+PW7 KM)JP0!T%: M-V=#=-A2\VXX_Z1W*XZ?\D9J!S6N&9J,+LXBL-W:Z!PR31C5E2$>_&!6O&G1 M^@0^7QN^J-[Q!8;=G?\&4$L#!!0 ( %EJKU99^ZZR/ @ (43 9 M>&PO=V]R:W-H965TB#RMQ)6U-;]^U^^[^4KETL5FK0H\61B;2X];N^R[M54R M9:$\ZR>#P6D_E[KH7%WP;_?VZL*4/M.%NK?"E7DN[>Y&969[V1EVZA\>]'+E MZ8?^U<5:+M6C\E_6]Q9W_49+JG-5.&T*8=7BLG,]?'Z%N3) MS)@GNKE++SL# J0R-?>D0>+?1MVJ+"-%@/&MTMEI3))@^[K6_H%]AR\SZ=2M MR?[4J5]==J8=D:J%+#/_8+9_J,J?$](W-YGCOV(;SHY''3$OG3=Y)0P$N2[" M?_F]BD-+8#KX@4!2"22,.QABE.^EEU<7UFR%I=/01A?L*DL#G"XH*8_>XJF& MG+]Z]&;^),R:0N3$.I/%1=]#+SWMSRL=-T%'\@,=(_'1%'[EQ&]%JM)#^3[P M-*"2&M1-\J;"C]+&8C3LBF20C-[0-VJ<'+&^T8^<7$FK>C=(7BKNY0Z<\N+: M6EDL%5__XWKFO 5!_OF:\T'W^'7=5#3OW%K.U64'5>&4W:C.U:^_#$\'YV\@ M'S?(QV]I_R_3\Z:.UQ'^W7@5C45/O+0@/A71>S57^4Q9D8PX"P/A5TK\;DVY M_O67:3*H'=N]AWXD]A:Z9;&+Q;6+ !2\FJ\:8G5?.2GD%DX!E3="0YW*UYG9*>78 M(XJ=GBM!3FIVJ8X;CJ]+*(='HES3[7#<'8Y'W>DX$=/NZ73"5X-XE(AQ=S(Y M[0X& ]R>3,5X.JAN!D/@"C=W#[V/*B7G8T&I^:=;O+O&'/ N@(Z.+A ,/AHQ9@#H&@RPN6%FZ8)4 M1Z[."MG"C+4RY$**PA2]N70KQ)T*HPKX>#(5)R,.) ?BM>JI!!S7!2$.:\9 M*NW)#= LE5A(;<5&9J4*&0HTXF(+?>QG/2PM+>Q'S_@B0M!_0INN*%U=OC>9 M1.:)#"93#OW+>JHD!M2CUD$' M477)(Q30E_@Q%BG3\;@6;$N" X,X.8VH-.:4K8W)X$"F_:XYOC\_'([CY$R< MG<2C"4Q.DW@RP9A)XA/<1@_:/?46E#Y-(T(Y+T!.U0#^VN@9Q:=#,6;0PZD8 MQB3=(,CT(F#GOEVCW@N?P&(\.8-8??5_&4_1'??6*/169@I6A>K'T/%[5<=O M]A64(+(?JA*U@$Q]*PUA,:'5?=I4P^36E.1&LX=\^GQ;]_@X^L-LT3ML=[\0 M03'>4;B4:&5P+1)(^DEHS$,KTV )RJ@H"^,14IJN/ QQ'%&(K.(-K?"RGD+[ MZNX*1[.P4DCR>Z6R?KW!JP%UK_;@215\0;<"T_U*AB823I$>I"$(IN@?P(4D MBXR:(QGG1T3&:AP>CM(FL+<EU&P M4-&9I/Z4-NRIM%E1B^6S^]WQ^88UB*=3\/J.-]C S;"G:E;!*ZJT0(*H+=7! MB.8X@(D565RY6* %$[P5!I>!(13?ON%$]S-1NR9:/:Z)+TD5,MLYS6L&R@ 3$(_0*R2/ (H5@K5D0SA!XU1: MFIC1NIQE>HX05.7 CPH-+-N5QN#@Q29\!FA26JYA5!2I?;W+TJX9!J%\.:!!3! DH\B'+AD=AOB 93PR/ELE70ED/',$ MBFA#!H5:+"!'7:5*"_52NN;A&$<5$K M2?-K\XWI.GQ:V1\/'ZBP&"PU,&5J =%!/#GI@ _\T2?<>+/F#RTSX[W)^7*E MP$E+!_!\8=#MJALRT'QYN_H/4$L#!!0 ( %EJKU8M?D[[\P8 0 9 M >&PO=V]R:W-H965TR+6TKIZ5M5:G?=6WI?OQL,7+Z4E7"IJ:7&E[FQE?!XM(N!JZT4 M13"JRD$V')X.*J%T[^8JO'NT-U>F\:72\M&2:ZI*V,V=+,WZNC?J;5]\4HNE MYQ>#FZM:+.23])_K1XNG0>>E4)743AE-5LZO>[>C=W=3GA\F?%%R[?;&Q"N9 M&?/"#P_%=6_(@&0I<\\>!/ZMY+TL2W8$&%];G[TN)!ONC[?>?PUKQUIFPLE[ M4_ZA"K^\[IWWJ)!ST93^DUG_+MOU!("Y*5WXI76<.[GH4=XX;ZK6& @JI>-_ M\:W-PY[!^? [!EEKD 7<,5! ^5YX<7-ES9HLSX8W'H2E!FN 4YJ+\N0MOBK8 M^9LG;_(7,C6GR%%="DU'SV)62G=\-? (P-,&>>OL+CK+ON-L3!^,]DM'O^A" M%J_M!P#6HB$LF$V?L/?N%OM./@;?V^U2V%E_PY5+.A1 M;$ N3[?6"KV08?ROVYGS%DSY]Z'%1]^3P[ZY>]ZY6N3RNH?V<-*N9._FYY]& MI\/+-Y!/.N23M[S?/*$;BZ:49.84:M:NXMY4Z$\G L5_^<9CZ0Z!?]/]8? _ M%#-!K?)ELBT6O7K,$K00^:7$GY6R7S%-DEI:90J23);_8?[Y*7EORE)81TD=-3[ M()PSB'DHWCIHG"SZ8H64+23-A;*T J* =*LB"S049I$W)*NZ-!N)%')ZF5A+R9B!= M_0_2>B"/@/JU53E/K$PA8YT/+281NWS",^(B!=BL$#HLR+VC'RW+_\OZ]XK3 M!+P;)4NDX\@A0TG(YH$T*-S&J5LW2$HU3QBWZ"CW1;USGB* MB.G9!;Q@M7#!53*A/AW:$6'N?_[I/!N=71;'R4-*W#Z_6=/4D2G#Y*%]^8@J:-]G MB11ZT]HXU@E4/TH'>@&5^MH8QF)TP/X1' R#>]/P,NB(3;/AY]F#8&S)V%F#)\#9&PEA46X/1((?D7*$=2LB)'@C)M2&X^4HA%(U&A%3$<6 M$BN#\FL?:0R*[[K[A-!I\!D=LOW.J=@>K7 L88D->6C1%1)K@:2"Z7XIHHC$ M6>P'98B&!?0#N%!D*EG!.7CXQ&3$F,UB8NF_$WL?$IN$H@$E]!G=:0%1]_/& M!I.8CI#O*$.O7@1<*YQ'T>K8_-'H($:Y(:D0U28F% ;'4/8J$&JQ74 E7I#V M-%!+?FT0J=S$RD3_KW#_A1#[N&F)6LVDU'OY:O>7EAZW<%FR)HS" O[1 " K M!#U:M4+QF*9Y/,(TFHE@YDF,T-*9K?X0-N@88<&")3;,I;J!YB#8#O;?T)VG M$_RONQ+RQX;>*7VL,K2 M;--NA.*O&S2("8*4G/FHDLGK%+]B6=@RGG&U'SGR#O5M9)1&)[YZ\%4#AXP6M>]M=;V_CK6XW M/=Z-<2Y8*$ JY1RFP_0,ASL;[YOQP9LZW/%FQN/&&(9+7-&EY0GX/C<0N_:! M W27_IL_ 5!+ P04 " !9:J]6>,S"M^\" #G" &0 'AL+W=O<$S8/I)S$6*E=Z*E2TS 3@J0"FU7P '67S87>V35+1%)@DG"& M!,1C:](9!GWC7SA\)["1.VMDE"PYOS>;+]'89H!; =Q#0/<(P*L WG,!W0K0+2I3 M2BGJ$&"%_9'@&R2,MV8SBZ*8!5K+)\P<^T()_91HG/(_ 0.!*3H-0&%");K! M0F!S%F?H';I;!.CTY R=(,+0MX3G$K-(CFRE(QN\'591IF44]T@4#UUSIA*) M/K((HGV\K3.NTW:W:4_=5L)K+"Z0USE'KN-Z#?G,G@]W&^!!.SR \!A\3XU7 M'X)7\'E'^+Z*%6;D+S8WX1S-.).#UG9*]W:_'4Z;([V/<) M6I/X3XF]6F*O5>(,RP3%NKNC6/ 4Z7EAKC=;E1V7* (2,5!-^DOBWHZT@7,H MOS7X2U^%5R+;JU._KE._M4Z3,,S3G.KK%)FY04+26)/^TW>BXUX>5J4UU$NK M\C3D8. ]1BS5VCLC( 6Q*D:I1"'/F2K;:FVMI_6D&%(']FEG."N'[B--^0F@ MF^:*,(DHQ)K2N7BOCTN48[7<*)X5@V;)E1Y;Q3+17R(@C(-^'G.NMAL3H/ZV M\?\!4$L#!!0 ( %EJKU83J HU=@, !\/ 9 >&PO=V]R:W-H965T MW!!5O&2A_8P2BG2YB#NLK/!>[L"B5B*622\8P( M6(RMB7LRHG\RP6,PUU3"C"<_6*3BL75DD0@6=)6H"[[Y F5 ?8T7\D2: M7[(I91V+A"NI>%HJHPEL245- G/T*7JG@[2KT'E#P2P7#G%UX9L(Z MI8H&(\$W1&AI1-,+PXW1QFA8IM,X5P*?,M13P1SK(EHE0/B"S!4/;]Y/D92( MS'B*E2*IX?KCK5Z#)&]/05&6R'?D/;F:GY*WK]^1UX1EY#+F*TFS2(YLA5YI M;#LL/9@6'G@/>."3,YZI6)*/60114]_&:*J0O&U(4Z\5\(R*0^*[!\1S/'^/ M/[/'JWLM[O@5P[[!\Q]B.*8"2E;/Z1]L 44F0M!L"7I]L&4W(L@?F=&<*9JP MOQ =D$G*5RC]\QM"DJ\*4OEK'[^%_=Y^^_H]<")S&L+8PD:7(-9@!6]>N0/G MPSYR.@)K4-6KJ.H]%_V2(RM$Z@HU;1N1L%:A^U@I3 V,*?TR6P>]X='(7M># MO2_3]RN11@C]*H1^6PC!!;I-11B;9)["&M^3N4EYF67R\PS2:Q![$]D*_=1$ M=@368&%0L3!XX9H?=$E51V -JH855B*KH[0FG3=71O=9U^UGM$F_KV;CC?L[;;) M?2'?V_DVV+51(P6Q-!.81/N8G^**7IU64][$S#8[YU,]_9D1Y@ZF&!WQ&[)D MF20)+!#2.1QB&ULQ5E=CZ,V%'WOK[!H5>U*NP%#OIM$FDE(NU6C1C/M[D.T#Y[@ M)&@ L[:33*3^^-K 0& =SZ1R-2\)&)]S[7/@XHM'1T(?V0YC#I[B*&%C:\=Y M.K1MMM[A&+$627$BKFP(C1$7IW1KLY1B%&2@.+)=Q^G:,0H3:S+*VI9T,B)[ M'H4)7E+ ]G&,Z.D61^0XMJ#UW' 7;G=<-MB348JV^![SO],E%6=VR1*$,4Y8 M2!) \69LW<#AW'4D(.OQ.<1'=G8,Y%0>"'F4)Y^"L>7($>$(K[FD0.+O@*W@M0J8TK@^?$S^SR;O)C, V)X2J(O8\9)7(#%".(PR?_14R'$&0!Z%P!N 7 ; +=[ > 5 M .^U@'8!:#>'U+X Z!2 SFL!W0+0S;3/Q4W$U%#@^N1>W:K"/," ;<,_)^A'\F4K+V0?P&45[E-E_P\2-ES># M=S/,41BQ]^ C^ G8@.T0Q6QD9=LE:Y\O!6/7 "F)!9YB!564HJ2+1:Y@8.'$SCOMT2GK/GFB&@ M5G\(2O")XYA]5;F;QV^KX\M\.&0I6N.Q)1(>P_2 K@WQM8.X5GQ#9#7Q>Z7XO>O%1T^7Q->371"_ MIQ)UT/$:HLX4_6"K[7::XFL'<:WXALAJXO=+\?M:O>Y"]@@V%&,0)AP+?@XH MXEAW]^L)5VVE 7V5 8[7A0T#U/T4-]=5S699$X0:#=V$"3AA1]EZU(GN!:M516ZE'=?* M2MOT2)@A01?$V4=,I55&:W=3;'6KJNH=ZBON1;Y6UJ= D_7RS"B;;Y1M;HJM M;D95S6Z= D]7WS"B;;Y1M;HJM;F7U;0#J:_FK4N +GP4NI$ ]"K;SB&!0 MI#(@6@)T4B=%5@379)SS?,BA;RQW=VVP?L]$^A<,95+3? MP,'0%U-27'&=H9]O#MM5Z'QK>8'H-DP8B/!&#,-I]<1[B.:[M?D))VFVN_A M."=Q=KC#*,!4=A#7-X3PYQ,9H-PSG_P+4$L#!!0 ( %EJKU8GTDFH50, M %@- 9 >&PO=V]R:W-H965TV MR#G@V(!2:GN.,[!33#(KF!C;D@<35DA*,EAR)(HTQ?S'#5"VGUJN=3!\)-M$ M:H,=3'*\A17(S_F2JY%=L\0DA4P0EB$.FZEU[8X7(^UO'+X0V(NC9Z17LF;L M7@_>QU/+T0$!A4AJ!JQN.Y@!I9I(A?&]XK3J*37P^/G OC!K5VM98P$S1K^2 M6"93:VBA&#:XH/(CV[^#:CU]S1<D'(Y=!JP233']8*\G56Z)P,EBI+S4N*""V02O)HGOT7ZXE%Q?H M"Z8%-O)?"_7=E6;T<@X2$RI>H9=+S"&3"4@28?H*O48OD(U$HJQB8DL5G)[" MCJI 9F4@WIE ?'3+%)E 819#?(JWU:+JE7F'ES.P;NMB3#KV7V#9]_3N9B+4A,5.FX0"M\+/?= MO\H5O9>0BF]-JI6\O69>7?;&(L<13"U5UP3P'5C!/W^[ ^=-4\J[) N[)%MT M1'8B3J\6I]?&'LS)CL20Q8AC"0W!W;3#[]Q&X4K0T(#T]K(+G(F].U;CMQYA MZ\3/37%'9"V+$MW=0KH&_@W]1%\QY_C(U)3- M5OKG_@9=DH5=DBTZ(CO1:%!K-/A#-6K0I3A=DH5=DBTZ(CL1YZH6YZKU!SK\ M(_ /"("4,Y)I*[ RQV_2996QN?*TB596)*-CBO?Y7!X6OP634Z#7NUTDL:A M]<@PJO,Z^EWQ_I3 7V\Y*W)4"(B1TZ26?=3AI<"WIA<7*&)%)LN-IK;6[?Z- MZ7(?V6?N>.XVV*^'XW#89!^-0W-LL/^?MCQSJ 9I2U1#2&&C0G NKU3MX&4? M7PXDRTW?N692=;'F,5%''^#:0;W?,"8/ SU!?9@*?@%02P,$% @ 66JO M5FLDO&M7!0 W", !D !X;"]W;W)K&ULQ5IM M;YLZ&/TK%G>ZVJ2M@"%OO4FD-MVT2;=;M:QW'Z;[P0U.@@J8:YNFE>Z/GPT4 M0T+<)C+*EX:WY_@YCWWPJ?%X0^@]6V/,P6,<)6QBK3E/SVV;+=8X1NR,I#@1 M=Y:$QHB+4[JR64HQ"O*@.+*AX_3M&(6)-1WGUV[H=$PR'H4)OJ& 97&,Z-,E MCLAF8KG6\X7OX6K-Y05[.D[1"L\QOTUOJ#BS*Y0@C''"0I( BI<3Z\(]GWF^ M#,B?^"?$&U8[!I+*'2'W\N1+,+$N"8)7S/P,0EPT(RW!:.*%GRF=0FU@->(G@'/?0^@ [V6 M?&:O#X>:=+RJREZ.Y^VKLBS8ATLQW (P(['0($/Y*+X0%4Y66.B"@[LG4'_N M!CWEER\VB ;@U]\"$GSA.&;_MM6W:-]O;U^^"\Y9BA9X8@FQ,TP?L#7]\P^W M[_S55AQ#8(U2^56I?!WZ]":CB[4H0#X6&#I>1/_*]P385;6-' M4NE75/HO4\G?F@%8U(9Q&Y\"J5_CXP^&6UQVG^EYU2.-# =5A@-MAM=A$L99 M#'Y=X_@.TU:I:!$.E8HAL ;9845V>.*WRM!DJ0R!-4HUJDHUTHZ+GW(J2S@# M8GX"5$[M# A3P[@X#Y,5X)C&;070HWK@"2/:]FJ::0./).LZ:E)W]#) CR_* M0 ]Q:.>:0FL2KKD8]\12*!,P52Y#:,UR054NV(D<7H!UG?V"T(<>RU@9,%=K M6J9B4,1B.!1V]UD6X'_PF@E##WUPUW?AKEQEKUS_U$HQY+;*SM:*7I8-Q=**]\N#)ZK')ZKMWA[=?*:&44+?7#'&T)K%D(927=P:IT8-:*F MT)KE4E;4U=JWXW6BA]4X+'WDL825H73UWN]C^8]I*95O^0H*^"9Z7"L10[ZP M+$$7+A,JEPF=$TL$&O6HIM":Y5(>%6I-7;G4%C*6B3H$&96R2#$-25 MJ!7W MEH0"V7RX:%_V*-NIKQ4,^\/![K*'/J%C"2N7"?5V<-Y@E5+!1Q(NV+82*_!& M-6+.F;?#J@LG"963A'HGV2[\'QNB%;X>]."1W(6'A,I#PE-[2&C40YI":Y9+ M>4CXP@J@,>'O+A+Z@T'?<9QMB71A(J$RD? 5ZX0'";_?(OS>]G*AOM5C62E' M"/5KBWN$OZ98/^?K80\>RUWX/*A\'CSUFB,TNNAH"JU9+N42H=XEFI/^:%?Z M0Z=%^5U80D]90D^_\'BP\DN\IO(==XN5OM5C62GGYNF=6[OR/Y&,:H6O1SWX MHUP79LY39LZ#I_Z$:7JPB5ZM0^^>I=H3/AE.W7A0Z=%^/I\CN6K+*&G M_VQ[N/#]%N'W_6U61IV;7=LG$6.ZRK>/,+ @6<*+O075U6J+RD6^,6/K^J5[ M/BLVFBB88M_+-:*K,&$@PDL!Z9P-1,?18BM)<<))FN_&N".7A/#G$]E M:%G^AM02P,$% @ 66JO5M\K4L0J P 2A( T !X M;"]S='EL97,N>&ULW5AM:]LP$/XK1EU'"Z-.XL6-UR2P!0J#;13:#_M6E%A. M!++DR4J7[-=/)SG.2W6EZX>MF4-JW3VZYQ[ISI7)L#9KP6X7C)EH50I9C\C" MF.I#'->S!2MI?:$J)BU2*%U28TT]C^M*,YK7$%2*N-?II'%)N23CH5R6UZ6I MHYE:2C,B_=85^=OG?$2ZZ7L2>;J)RMF(W)^]_;%4YNI-Y.\G[TY..O?G5X?^ M,P>E;46"X MX+@IRGA8*+FM34*\P[+3DD4/5(S(A H^U1RB"EIRL?;N'CAF2B@=&=L4-ET7 M//4O#W>]!?W2\)1<*NUR^PS^[[29?@!L+!#(A6@%]HAWC(<5-89I>6T--]DY M'T%1,[Y;5U;A7--UM]J)MNA%=0,/8TW@'^7S7/O MTKZ,-ZKX@S*?EG8YTMG0:>Q&LX*OG+TJ6@$8>Q=GIU4EUA\%G\N2^<4_.^%X M2#=QT4)I_LMF@U:960?3)'I@VO#9KN>GIM4=6YE-.ZT*7'/O"#7_W7V>,\DT M%;NB;>^_YEU^L>+D\E])=O]5#@4'-38GY&L7V3\&D>DQB#R*GAR\2I%Q U9T2^P4N3V":-IDLN#)>-M>!YSN2C4]C2&SJU+\I[_'9^S@JZ M%.:N!4=D._[*3]TPL@.; MM;D@X!"Y=E<8P6(\%D8 P_)@"K 8'X7E^9_6,T#7XS%,VR"(#-"8 1KCHT+( MQ'VP/.&8S%[AE699DJ0IMJ.325#!!-NW-(5OF W3!A%8'LCT9WN-5QOOD*?[ M *OI4QV"K13O1&RE^%X#$MXWB,BR<+6Q/!"!50'K'<@?S@,]%8Y)$J@JI@U[ M@G$DRS $>C'-8?20$3; M8T.P6BP^0"X99K>]9!:G]&(.J&]>'DRW.'CPP'WY>:@S6ZM]8[]+*6R M6;1UKIK&L@R%-H4W)'7;.);66 "[L%<*6,!TDRB4N.*KJ].<9: MF-CO: >Y0ZW(V!A6" ?[Q]]TV1XMKE&B^Y5%;5M"Q$I46.(+B"Q*(F:W^O!9 M&WS1RG&YS(V6,HO2SK$"XS!_8UXVD-_XVK86Q]=?.8%DT22A@ 4:Z]H1;7Q. MC'N@P5VO=OH!I0,SXPX>C:XK5)LF#*TB]I;1YN'X[9(X-?^21ET4F,-,YW4) MRG5Y-" ;0&6W6-F(*5Y"%MWK/9AF/33!7'1K9 M' <@Q^>$''J0DP#DI%_(1U!@N/1@+@,PE_W"S!65-2S9=\5K@4VR'E#1W4 N MV5P5'N15 /*J7\@E;A326*X<^Y3GNE:."C!;T ;G"-:#O Y 7O<,Z72^8[IJ M':RB N/7Z214J)/_3<8N2-LDV'<^8E!+>A:3WW>"7"/")X@A M)4E[EI(EQ1"U!*8+UF;TPQWO*DU)4?U#F(:T).U93-Y@LN=NX]^S%9>UCQE2 MD[1G.0EBGLA)&M*3M&=!^=O5\8ZHCQE2E+25E/CX/A10H +Q1%-8LM-;-5\8 MUGRZ4SX:IU3(BEK*>[(]JR^:B^-S\_A4OGT%4$L#!!0 ( %EJKU9*A+N9 M"@$ (<* : >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-ULV.@C 0 MP/%7(7T AT%%W8BGO7@UOD"#PT<$VK2S4=]^"1YPS![V8MH3:0G3WZ7_L#]1 MI[DU@V]:ZY-[WPV^4 VS_0+P94.]]@MC:1C?5,;UFL>EJ\'J\JIK@BQ-BJ:JVI&]3_O0T\!^#X6;#>S=L>I@-!*@%;A06L!6H<'Y0*4AP=M!&@3'K05 MH&UXT$Z =N%!F,HRIA&0WF(=0:U1YAHCZ#7*8&,$Q4:9;(R@V2BCC1%4&V6V M\9/=]OSHR,^>YUJ>_\E,\_@MS<=/R^?FVQV?T@SBO_/P"U!+ P04 " !9 M:J]6(]P]E%0! #."P $P %M#;VYT96YT7U1Y<&5S72YX;6S-EMM.PS , MAE^EZNW49ADP#MIV ]S"+GB!T+IKM9P49V-[>]SN((%&Q30D?-.HL?U_?V+) MRN1MZP&3C=$6IVD=HW\0 HL:C,+<>; 4J5PP*M)O6 BOBJ5:@!@-AV-1.!O! MQBRV&NEL\@256NF8/&]H&QMGIVD C6GRN$ML6=-4>:^;0D6*B[4MOU&R/2&G MRBX'Z\;C@!)2<9+01GX&[.M>UQ!"4T(R5R&^*$-98J,%QJT&S/LE3GAT5=44 M4+IB9:@D1Q] E5@#1*/SG>B@GQSIAF'WE1?S.YD^(&7.@_-('0MP/N[0DK8Z M\R0$(3;]1SP22?KB\T';[1+*7[+I>C]<6';]0-$ME]_QUQX?]<_T,6+BXXJ) MCVLF/FZ8^!@S\7'+Q,<=$Q_W3'S((19*KD,5,GWT"4$L! A0#% @ 66JO5@=!36*! L0 M ! ( ! &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4 M" !9:J]6U<,!2^\ K @ $0 @ &O 9&]C4')O<',O M8V]R92YX;6Q02P$"% ,4 " !9:J]6F5R<(Q & "<)P $P M @ '- 0 >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( %EJKU:) MOXY\604 #<< 8 " @0X( !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ M66JO5M(_EA;V @ = @ !@ ("!TA( 'AL+W=O&PO=V]R M:W-H965T&UL4$L! A0#% @ 66JO5C_!51$3!0 <10 M !@ ("!<1X 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 66JO5N8&,BF, @ QP4 !@ ("! M9B\ 'AL+W=O&UL4$L! A0#% @ 66JO5BU^3OOS!@ ! !D M ("!FSH 'AL+W=O,S"M^\" #G" &0 @('%00 >&PO=V]R:W-H M965TM$ !X;"]W;W)K&UL4$L! M A0#% @ 66JO5O 1H=DH!0 /Q\ !D ("!F$@ 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 66JO M5M\K4L0J P 2A( T ( !$5< 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ 66JO5DJ$ MNYD* 0 APH !H ( !S%T 'AL+U]R96QS+W=O XML 29 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 30 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 31 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 49 94 1 true 14 0 false 6 false false R1.htm 00000001 - Document - Cover Sheet http://ir-medical.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://ir-medical.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://ir-medical.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://ir-medical.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) Sheet http://ir-medical.com/role/StatementsOfChangesInStockholdersEquity Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://ir-medical.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - General Sheet http://ir-medical.com/role/General General Notes 7 false false R8.htm 00000008 - Disclosure - Interim Unaudited Financial Information Sheet http://ir-medical.com/role/InterimUnauditedFinancialInformation Interim Unaudited Financial Information Notes 8 false false R9.htm 00000009 - Disclosure - Significant Accounting Policies Sheet http://ir-medical.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Stock options plan Sheet http://ir-medical.com/role/StockOptionsPlan Stock options plan Notes 10 false false R11.htm 00000011 - Disclosure - Stock options plan (Tables) Sheet http://ir-medical.com/role/StockOptionsPlanTables Stock options plan (Tables) Tables http://ir-medical.com/role/StockOptionsPlan 11 false false R12.htm 00000012 - Disclosure - General (Details Narrative) Sheet http://ir-medical.com/role/GeneralDetailsNarrative General (Details Narrative) Details http://ir-medical.com/role/General 12 false false R13.htm 00000013 - Disclosure - Schedule of Stock-Based Compensation Expenses (Details) Sheet http://ir-medical.com/role/ScheduleOfStock-basedCompensationExpensesDetails Schedule of Stock-Based Compensation Expenses (Details) Details 13 false false R14.htm 00000014 - Disclosure - Schedule of Stock Options, Valuation Assumptions (Details) Sheet http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails Schedule of Stock Options, Valuation Assumptions (Details) Details 14 false false R15.htm 00000015 - Disclosure - Schedule of Stock Options, Valuation Assumptions (Details) (Parenthetical) Sheet http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetailsParenthetical Schedule of Stock Options, Valuation Assumptions (Details) (Parenthetical) Details 15 false false R16.htm 00000016 - Disclosure - Stock options plan (Details Narrative) Sheet http://ir-medical.com/role/StockOptionsPlanDetailsNarrative Stock options plan (Details Narrative) Details http://ir-medical.com/role/StockOptionsPlanTables 16 false false All Reports Book All Reports [dq-0548-EntityAddressPostalZipCode-Missing] Submission type 10-Q should have a non-empty value for EntityAddressPostalZipCode in the Required Context. form10-q.htm [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:WarrantsAndRightsOutstandingTerm - form10-q.htm 42, 43 form10-q.htm ex31-1.htm ex31-2.htm ex32-1.htm ex32-2.htm irme-20230331.xsd irme-20230331_cal.xml irme-20230331_def.xml irme-20230331_lab.xml irme-20230331_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 34 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-q.htm": { "axisCustom": 0, "axisStandard": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 179, "http://xbrl.sec.gov/dei/2023": 26 }, "contextCount": 49, "dts": { "calculationLink": { "local": [ "irme-20230331_cal.xml" ] }, "definitionLink": { "local": [ "irme-20230331_def.xml" ] }, "inline": { "local": [ "form10-q.htm" ] }, "labelLink": { "local": [ "irme-20230331_lab.xml" ] }, "presentationLink": { "local": [ "irme-20230331_pre.xml" ] }, "schema": { "local": [ "irme-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 178, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 14, "http://ir-medical.com/20230331": 3, "http://xbrl.sec.gov/dei/2023": 4, "total": 21 }, "keyCustom": 6, "keyStandard": 88, "memberCustom": 4, "memberStandard": 10, "nsprefix": "IRME", "nsuri": "http://ir-medical.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://ir-medical.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Stock options plan", "menuCat": "Notes", "order": "10", "role": "http://ir-medical.com/role/StockOptionsPlan", "shortName": "Stock options plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Stock options plan (Tables)", "menuCat": "Tables", "order": "11", "role": "http://ir-medical.com/role/StockOptionsPlanTables", "shortName": "Stock options plan (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - General (Details Narrative)", "menuCat": "Details", "order": "12", "role": "http://ir-medical.com/role/GeneralDetailsNarrative", "shortName": "General (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:NatureOfOperations", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "-3", "lang": null, "name": "IRME:NetCashFlowsProvidedByUsedInOperatingActivities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Schedule of Stock-Based Compensation Expenses (Details)", "menuCat": "Details", "order": "13", "role": "http://ir-medical.com/role/ScheduleOfStock-basedCompensationExpensesDetails", "shortName": "Schedule of Stock-Based Compensation Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-012023-03-31_us-gaap_ResearchAndDevelopmentExpenseMember", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Schedule of Stock Options, Valuation Assumptions (Details)", "menuCat": "Details", "order": "14", "role": "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails", "shortName": "Schedule of Stock Options, Valuation Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Schedule of Stock Options, Valuation Assumptions (Details) (Parenthetical)", "menuCat": "Details", "order": "15", "role": "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetailsParenthetical", "shortName": "Schedule of Stock Options, Valuation Assumptions (Details) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R16": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Stock options plan (Details Narrative)", "menuCat": "Details", "order": "16", "role": "http://ir-medical.com/role/StockOptionsPlanDetailsNarrative", "shortName": "Stock options plan (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "menuCat": "Statements", "order": "2", "role": "http://ir-medical.com/role/BalanceSheets", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://ir-medical.com/role/BalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://ir-medical.com/role/StatementsOfOperations", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://ir-medical.com/role/StatementsOfChangesInStockholdersEquity", "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://ir-medical.com/role/StatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "-3", "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - General", "menuCat": "Notes", "order": "7", "role": "http://ir-medical.com/role/General", "shortName": "General", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Interim Unaudited Financial Information", "menuCat": "Notes", "order": "8", "role": "http://ir-medical.com/role/InterimUnauditedFinancialInformation", "shortName": "Interim Unaudited Financial Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Significant Accounting Policies", "menuCat": "Notes", "order": "9", "role": "http://ir-medical.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 14, "tag": { "IRME_DecreaseIncreaseInNonCurrentAssetsFromRecordingOfRightsOfUseAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "(Decrease) increase in non-current assets from recording of rights of use assets" } } }, "localname": "DecreaseIncreaseInNonCurrentAssetsFromRecordingOfRightsOfUseAssets", "nsuri": "http://ir-medical.com/20230331", "presentation": [ "http://ir-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "IRME_EmployeeStockOptionFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Stock Option Four [Member]" } } }, "localname": "EmployeeStockOptionFourMember", "nsuri": "http://ir-medical.com/20230331", "presentation": [ "http://ir-medical.com/role/StockOptionsPlanDetailsNarrative" ], "xbrltype": "domainItemType" }, "IRME_EmployeeStockOptionOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Stock Option One [Member]" } } }, "localname": "EmployeeStockOptionOneMember", "nsuri": "http://ir-medical.com/20230331", "presentation": [ "http://ir-medical.com/role/StockOptionsPlanDetailsNarrative" ], "xbrltype": "domainItemType" }, "IRME_EmployeeStockOptionThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Stock Option Three [Member]" } } }, "localname": "EmployeeStockOptionThreeMember", "nsuri": "http://ir-medical.com/20230331", "presentation": [ "http://ir-medical.com/role/StockOptionsPlanDetailsNarrative" ], "xbrltype": "domainItemType" }, "IRME_EmployeeStockOptionTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Stock Option Two [Member]" } } }, "localname": "EmployeeStockOptionTwoMember", "nsuri": "http://ir-medical.com/20230331", "presentation": [ "http://ir-medical.com/role/StockOptionsPlanDetailsNarrative" ], "xbrltype": "domainItemType" }, "IRME_IncreaseDecreaseInAccruedFinancialExpenses": { "auth_ref": [], "calculation": { "http://ir-medical.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "IncreaseDecreaseInAccruedFinancialExpenses", "negatedLabel": "Accrued financial income" } } }, "localname": "IncreaseDecreaseInAccruedFinancialExpenses", "nsuri": "http://ir-medical.com/20230331", "presentation": [ "http://ir-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "IRME_IncreaseDecreaseInNonCurrentLiabilitiesFromRecordingOfLiabilityOfLeaseAgreements": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Increase (decrease) in non-current liabilities from recording of liability of lease agreements" } } }, "localname": "IncreaseDecreaseInNonCurrentLiabilitiesFromRecordingOfLiabilityOfLeaseAgreements", "nsuri": "http://ir-medical.com/20230331", "presentation": [ "http://ir-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "IRME_IncreaseInLongTermDeposit": { "auth_ref": [], "calculation": { "http://ir-medical.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "IncreaseInLongTermDeposit", "negatedLabel": "increase in long term deposit" } } }, "localname": "IncreaseInLongTermDeposit", "nsuri": "http://ir-medical.com/20230331", "presentation": [ "http://ir-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "IRME_LongTermRestrictedDeposit": { "auth_ref": [], "calculation": { "http://ir-medical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Long term restricted deposit" } } }, "localname": "LongTermRestrictedDeposit", "nsuri": "http://ir-medical.com/20230331", "presentation": [ "http://ir-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "IRME_NetCashFlowsProvidedByUsedInOperatingActivities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net cash flows provided by used in operating activities.", "label": "NetCashFlowsProvidedByUsedInOperatingActivities", "negatedLabel": "Cash flow from operating activities net" } } }, "localname": "NetCashFlowsProvidedByUsedInOperatingActivities", "nsuri": "http://ir-medical.com/20230331", "presentation": [ "http://ir-medical.com/role/GeneralDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r289", "r291", "r292" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir-medical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_MaximumMember": { "auth_ref": [ "r97", "r98", "r99", "r100", "r114", "r179", "r191", "r201", "r202", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r262", "r263", "r264", "r267", "r307", "r315", "r316", "r317", "r318", "r319", "r320" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails", "http://ir-medical.com/role/StockOptionsPlanDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r97", "r98", "r99", "r100", "r114", "r179", "r191", "r201", "r202", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r262", "r263", "r264", "r267", "r307", "r315", "r316", "r317", "r318", "r319", "r320" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails", "http://ir-medical.com/role/StockOptionsPlanDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r97", "r98", "r99", "r100", "r113", "r114", "r142", "r143", "r144", "r178", "r179", "r191", "r201", "r202", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r262", "r263", "r264", "r267", "r270", "r304", "r307", "r316", "r317", "r318", "r319", "r320" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails", "http://ir-medical.com/role/StockOptionsPlanDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r97", "r98", "r99", "r100", "r113", "r114", "r142", "r143", "r144", "r178", "r179", "r191", "r201", "r202", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r262", "r263", "r264", "r267", "r270", "r304", "r307", "r316", "r317", "r318", "r319", "r320" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails", "http://ir-medical.com/role/StockOptionsPlanDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r6" ], "calculation": { "http://ir-medical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Trade and other payables" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r90", "r91" ], "calculation": { "http://ir-medical.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r21", "r266", "r323" ], "calculation": { "http://ir-medical.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r149", "r150", "r151", "r199", "r300", "r301", "r302", "r309", "r324" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r15", "r16", "r117" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "verboseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile loss for the period to net cash" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_Assets": { "auth_ref": [ "r39", "r49", "r61", "r84", "r86", "r88", "r92", "r101", "r102", "r103", "r104", "r105", "r106", "r107", "r109", "r110", "r155", "r157", "r168", "r183", "r222", "r266", "r277", "r305", "r306", "r313" ], "calculation": { "http://ir-medical.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets [Default Label]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r46", "r51", "r61", "r92", "r101", "r102", "r103", "r104", "r105", "r106", "r107", "r109", "r110", "r155", "r157", "r168", "r266", "r305", "r306", "r313" ], "calculation": { "http://ir-medical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r61", "r92", "r101", "r102", "r103", "r104", "r105", "r106", "r107", "r109", "r110", "r155", "r157", "r168", "r305", "r306", "r313" ], "calculation": { "http://ir-medical.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets, Noncurrent", "totalLabel": "Total non-current assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non- current assets" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r120", "r121", "r122", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StockOptionsPlanDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r11", "r48", "r258" ], "calculation": { "http://ir-medical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r11", "r31", "r59" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash and cash equivalents as at the end of the period", "periodStartLabel": "Cash and cash equivalents as at the beginning of the period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r0", "r31" ], "calculation": { "http://ir-medical.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net Decrease in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-cash transactions:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Warrant exercise price per share" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails", "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetailsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r268", "r269", "r270", "r272", "r273", "r274", "r275", "r300", "r301", "r309", "r322", "r324" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StatementsOfChangesInStockholdersEquity", "http://ir-medical.com/role/StockOptionsPlanDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r20", "r210" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r4", "r20", "r210", "r228", "r324", "r325" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r20", "r185", "r266" ], "calculation": { "http://ir-medical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, par value $0.001 per share, 250,000,000, shares authorized. as of March 31, 2023 and December 31, 2022; 68,829,424 and 68,808,970 shares issued, respectively." } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r2", "r12" ], "calculation": { "http://ir-medical.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r115", "r119", "r146", "r147", "r148", "r265" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Stock options plan" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StockOptionsPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r57", "r67", "r68", "r69", "r70", "r71", "r75", "r76", "r78", "r79", "r80", "r81", "r166", "r167", "r181", "r190", "r259" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic and dilutive loss per common stock (in dollars)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r312" ], "calculation": { "http://ir-medical.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/ScheduleOfStock-basedCompensationExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r4", "r44", "r54", "r55", "r56", "r62", "r63", "r64", "r66", "r72", "r74", "r83", "r93", "r94", "r112", "r149", "r150", "r151", "r153", "r154", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r169", "r170", "r171", "r172", "r173", "r174", "r176", "r192", "r193", "r194", "r199", "r248" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails", "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetailsParenthetical", "http://ir-medical.com/role/StatementsOfChangesInStockholdersEquity", "http://ir-medical.com/role/StockOptionsPlanDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r28", "r232" ], "calculation": { "http://ir-medical.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/ScheduleOfStock-basedCompensationExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r95", "r96", "r233" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/ScheduleOfStock-basedCompensationExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r96", "r233" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/ScheduleOfStock-basedCompensationExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "auth_ref": [ "r1" ], "calculation": { "http://ir-medical.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.", "label": "(Decrease) increase in trade and other payables" } } }, "localname": "IncreaseDecreaseInAccountsPayableTrade", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r1" ], "calculation": { "http://ir-medical.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Increase in accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r7", "r61", "r92", "r101", "r102", "r103", "r104", "r105", "r106", "r107", "r109", "r110", "r156", "r157", "r158", "r168", "r209", "r260", "r277", "r305", "r313", "r314" ], "calculation": { "http://ir-medical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r25", "r40", "r187", "r266", "r298", "r303", "r311" ], "calculation": { "http://ir-medical.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r9", "r47", "r61", "r92", "r101", "r102", "r103", "r104", "r105", "r106", "r107", "r109", "r110", "r156", "r157", "r158", "r168", "r266", "r305", "r313", "r314" ], "calculation": { "http://ir-medical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r5", "r184" ], "calculation": { "http://ir-medical.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.", "label": "Long term lease liability" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketingExpense": { "auth_ref": [ "r28" ], "calculation": { "http://ir-medical.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs.", "label": "Marketing expenses" } } }, "localname": "MarketingExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r42", "r43" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "General" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/General" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r58" ], "calculation": { "http://ir-medical.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r31", "r32", "r33" ], "calculation": { "http://ir-medical.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r26", "r33", "r41", "r45", "r52", "r53", "r56", "r61", "r65", "r67", "r68", "r69", "r70", "r73", "r74", "r77", "r84", "r85", "r87", "r89", "r92", "r101", "r102", "r103", "r104", "r105", "r106", "r107", "r109", "r110", "r167", "r168", "r189", "r230", "r246", "r247", "r261", "r276", "r305" ], "calculation": { "http://ir-medical.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://ir-medical.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Loss for the period", "negatedLabel": "Net losses", "negatedTotalLabel": "Loss for the period" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/GeneralDetailsNarrative", "http://ir-medical.com/role/StatementsOfCashFlows", "http://ir-medical.com/role/StatementsOfChangesInStockholdersEquity", "http://ir-medical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r29" ], "calculation": { "http://ir-medical.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedLabel": "Financial income, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r84", "r85", "r87", "r89", "r261" ], "calculation": { "http://ir-medical.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "negatedTotalLabel": "Total operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r175" ], "calculation": { "http://ir-medical.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right of use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r8", "r266" ], "calculation": { "http://ir-medical.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Stockholders\u2019 loans" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration": { "auth_ref": [ "r50", "r108", "r177", "r299" ], "lang": { "en-us": { "role": { "documentation": "Indicates related and nonrelated party status for liability classified as other and current.", "label": "Other Liability, Current, Related and Nonrelated Party Status [Extensible Enumeration]" } } }, "localname": "OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/BalanceSheetsParenthetical" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r30" ], "calculation": { "http://ir-medical.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails", "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetailsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r3", "r182", "r188", "r266" ], "calculation": { "http://ir-medical.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Quarterly Financial Information Disclosure [Abstract]" } } }, "localname": "QuarterlyFinancialInformationDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r35", "r82" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Interim Unaudited Financial Information" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/InterimUnauditedFinancialInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r18", "r152", "r321" ], "calculation": { "http://ir-medical.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/ScheduleOfStock-basedCompensationExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r22", "r37", "r186", "r195", "r196", "r198", "r211", "r266" ], "calculation": { "http://ir-medical.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/BalanceSheets", "http://ir-medical.com/role/GeneralDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r44", "r62", "r63", "r64", "r66", "r72", "r74", "r93", "r94", "r149", "r150", "r151", "r153", "r154", "r159", "r161", "r162", "r164", "r165", "r192", "r194", "r199", "r324" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails", "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetailsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/ScheduleOfStock-basedCompensationExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule of Stock-Based Compensation Expenses" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StockOptionsPlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r116", "r118", "r120", "r121", "r122", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails", "http://ir-medical.com/role/StockOptionsPlanDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Stock Options, Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StockOptionsPlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpenseMember": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling and marketing expense.", "label": "Selling and Marketing Expense [Member]" } } }, "localname": "SellingAndMarketingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/ScheduleOfStock-basedCompensationExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r1" ], "calculation": { "http://ir-medical.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock based compensation", "terseLabel": "Share based compensation", "verboseLabel": "Total stock based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/ScheduleOfStock-basedCompensationExpensesDetails", "http://ir-medical.com/role/StatementsOfCashFlows", "http://ir-medical.com/role/StockOptionsPlanDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Dividend yields", "verboseLabel": "Dividend rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails", "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetailsParenthetical" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected volatility maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected volatility minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk free interest rate maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk free interest rate minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [ "r116", "r118", "r120", "r121", "r122", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails", "http://ir-medical.com/role/StockOptionsPlanDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Stock-based compensation, shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r120", "r121", "r122", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StockOptionsPlanDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected life (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Shares vested grant" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StockOptionsPlanDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares issued price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StockOptionsPlanDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r34", "r60" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r4", "r10", "r44", "r54", "r55", "r56", "r62", "r63", "r64", "r66", "r72", "r74", "r83", "r93", "r94", "r112", "r149", "r150", "r151", "r153", "r154", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r169", "r170", "r171", "r172", "r173", "r174", "r176", "r192", "r193", "r194", "r199", "r248" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails", "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetailsParenthetical", "http://ir-medical.com/role/StatementsOfChangesInStockholdersEquity", "http://ir-medical.com/role/StockOptionsPlanDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r62", "r63", "r64", "r83", "r180", "r197", "r200", "r203", "r204", "r205", "r206", "r207", "r208", "r210", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r223", "r224", "r225", "r226", "r227", "r229", "r231", "r232", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r248", "r271" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r62", "r63", "r64", "r83", "r180", "r197", "r200", "r203", "r204", "r205", "r206", "r207", "r208", "r210", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r223", "r224", "r225", "r226", "r227", "r229", "r231", "r232", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r248", "r271" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": { "auth_ref": [ "r13", "r17" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock-based compensation" } } }, "localname": "StockGrantedDuringPeriodValueSharebasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r4", "r19", "r20", "r37" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Purchase plans employees" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StockOptionsPlanDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock issued during period shares issued for services" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StockOptionsPlanDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r20", "r23", "r24", "r36", "r212", "r228", "r249", "r250", "r266", "r277", "r298", "r303", "r311", "r324" ], "calculation": { "http://ir-medical.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total Stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/BalanceSheets", "http://ir-medical.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails", "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_WarrantMember": { "auth_ref": [ "r268", "r269", "r272", "r273", "r274", "r275" ], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails", "http://ir-medical.com/role/ScheduleOfStockOptionsValuationAssumptionsDetailsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and rights outstanding term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir-medical.com/role/StockOptionsPlanDetailsNarrative" ], "xbrltype": "durationItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480513/718-10-30-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480843/718-30-35-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r278": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r279": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r281": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r282": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r283": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r284": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r285": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r286": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r287": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r288": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r289": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r291": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r292": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r293": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r294": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r295": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r296": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r297": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r34": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r35": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "270", "URI": "https://asc.fasb.org//270/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org//275/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 35 0001493152-23-017120-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-017120-xbrl.zip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end